The Effects of Antiretroviral Access on the Creation and Maintanence of HIV-Seropositive Identity. by Peplinski, Kyle Patrick
Georgia State University
ScholarWorks @ Georgia State University
Anthropology Theses Department of Anthropology
7-14-2008
The Effects of Antiretroviral Access on the Creation
and Maintanence of HIV-Seropositive Identity.
Kyle Patrick Peplinski
Follow this and additional works at: https://scholarworks.gsu.edu/anthro_theses
Part of the Anthropology Commons
This Thesis is brought to you for free and open access by the Department of Anthropology at ScholarWorks @ Georgia State University. It has been
accepted for inclusion in Anthropology Theses by an authorized administrator of ScholarWorks @ Georgia State University. For more information,
please contact scholarworks@gsu.edu.
Recommended Citation
Peplinski, Kyle Patrick, "The Effects of Antiretroviral Access on the Creation and Maintanence of HIV-Seropositive Identity.." Thesis,
Georgia State University, 2008.
https://scholarworks.gsu.edu/anthro_theses/26
  
THE EFFECTS OF ANTIRETROVIRAL ACCESS ON THE CREATION AND 
MAINTENENCE OF HIV-SEROPOSITIVE IDENTITY 
 
by 
 
KYLE P. PEPLINSKI 
 
Under the Direction of Cassandra White, PhD. 
 
ABSTRACT 
 
 The study of identity based on the presence of disease has traditionally focused on 
landmark events, such as diagnosis or the introduction of treatment options.  These events 
have been shown to significantly alter so-called “illness identities.”  The project was 
undertaken in Atlanta, GA, which has a relatively high rate of HIV infection and a large 
number of HIV-related services and support mechanisms.  This study contextualizes 
illness identities within a larger socio-political and economic paradigm, recognizing that 
individuals use multiple identities to inform their interactions and decisions, specifically 
those regarding the beginning and continuation of antiretroviral (ARV) treatment.  In 
addition, structural barriers which limit one’s access to ARV treatment are considered 
within a context of social and economic marginalization and inequitable power 
relationships within a post-industrial Western society.    
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 1 
Chapter 1 
“Long-term chemotherapy:” Introduction and the Access 
Landscape Today. 
  
The global HIV/AIDS pandemic has affected nearly 40 million people worldwide, 
with over 1.2 million of those cases being reported in the United States (WHO 2008).  
While these statistics illustrate an enormous public health challenge, they also imply a 
larger political, social, and economic tragedy.  In the last 10 years, effective medications, 
known as antiretrovirals (ARV) or antiretroviral treatment (ART), have been developed 
to extend and improve the quality of life of people living with HIV/AIDS.  These 
medications are effective in maintaining high CD4 white blood cell counts and reducing 
viral loads, in many cases to undetectable levels, which are important signifiers in HIV 
healthcare.  However, they are often prohibitively expensive to the individual.  Providing 
these pharmaceuticals to those who need them has been a major challenge and focus for 
global, national, and local stakeholders throughout the world.  Although public health 
authorities are almost exclusively concerned with the healthcare benefits of adherent use 
of ART, anthropologists have long considered the social and economic ramifications of 
ART use.  An important component to this line of questioning is how access to and 
utilization of ART affects identity for HIV-positive individuals.  
The United States has seen a tremendous effort to provide for and support 
treatment options for people living with HIV/AIDS, both through governmental and 
private channels.  Private insurance and a multitude of non-profit organizations have been 
providing access to ART since 1996, and to ART’s predecessors since 1987.  The United 
States government has provided access, through Medicaid and Medicare, since 1990 and 
has developed numerous other programs to subsidize ART since then.  However, 
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although there are numerous routes through which to garner access in the United States, 
many people living with HIV are not utilizing it.  Why these people “choose” to forgo 
treatment has many explanations and outcomes.  It has been shown that adherent use of 
ART can beneficially impact quality of life measurements (Mannheimer et al. 2005).  
This result, then, begs the question, if access to ART is provided for to a significant 
majority of people living with HIV in the United States, why are utilization rates not 
universal among the United States population?  Of course, the answer to this question is 
multi-faceted and, in many cases, ambiguous.  There are both personal and structural 
limitations affecting who utilizes ART and when they do so.  Although the United States 
has attempted to remedy the structural barriers to ART access, underlying issues of 
poverty, education, and class, gender, and race inequality exist as general impediments to 
healthcare access, and HIV-related healthcare is no exception.  Identifying these 
structural limitations is a major responsibility of critical social science and a first step in 
alleviating the inequalities they create. 
 While these structural barriers have, to some extent, more recently received the 
attention of anthropologists and other social scientists, especially in a U.S. context, 
personal factors affecting the utilization of ART have long been, and continue to be, a 
focus of the field.  Parker and Aggleton note, in the context of anthropological research 
on HIV/AIDS, that, “much work has tended to focus on stereotyping rather than on the 
structural conditions that produce exclusion from social and economic life” (Parker and 
Aggleton 2003: 15).  For the purpose of this paper, I am defining personal traits as 
psychological and emotional states or values that, in one way or another, affect the 
decision making process of an individual.  It should be noted that these are not absolute 
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categories and certain characteristics, most notably stigma, fall in a grey area somewhere 
between what is emotional/psychological and what is structural.  In illustrating this point, 
Scheper-Hughes and Lock (1987) note that, “Sickness is not just an isolated event, nor an 
unfortunate brush with nature.  It is a form of communication-the language of the organs-
through which nature, society, and culture speak simultaneously” (Scheper-Hughes and 
Lock 1987: 31).  The undeniable link between mind/body, cultural/biomedical, and 
personal/structural must be taken into account with any holistic study of illness and 
health.  These categories are not meant to be dichotomous, but continuums of experience 
and effect on any individual or collective.  It should also be noted that there were several 
early studies which focused on the risk of acquiring HIV/AIDS through the structural 
prisms of economic, social, and gender inequality (Schoepf 1995; Singer et al. 1990).  
This study is an effort to weave the personal and structural factors affecting access to 
HIV treatment and the subsequent effects of that treatment on identity creation into a 
coherent statement on the challenges confronting people living with HIV/AIDS today.   
 To this end, my research has been heavily influenced by the theoretical paradigm 
introduced by Michel Foucault (1973) in The Birth of the Clinic: An Archeology of 
Medical Perception.  In this work, Foucault examines the roles of the “doctor,” patient, 
and healthcare system on the medical experience.  He develops the clinical gaze as an 
explanatory tool for the hegemonic control of biomedicine over the clinical experience.  
The clinical gaze, as Foucault posits, is an epicenter of knowledge and authority which 
only a “doctor,” someone who has been trained in biomedicine, can possess.  This 
knowledge base allows the healthcare professional to interpret symptoms, signs of illness, 
into meaningful and culturally salient entities.  The “doctor” becomes a translator of 
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biology and the patient is, in effect, told how to respond to and understand his illness.   
The concept of the clinical gaze has been extremely influential to the field of medical 
anthropology, and others have extended the gaze to include social settings, which I will 
expand upon in chapter 3.  However, in Foucault’s conception of the gaze, medical 
authority and knowledge was tied to not only physical manifestations of disease, 
symptoms, but also to specialized training in medicine.  There are, however, several 
critiques of this understanding.   
First, especially in the case of HIV, there are long periods of time when no 
physical symptoms are manifest but the diagnosis has already been made.  Although the 
act of diagnosis falls within Foucault’s original paradigm, where HIV antibodies 
constitute the visible “symptoms” which are interpreted and related to the patient, the 
incubatory stage of HIV has few, if any, visible symptoms to record, “visualize,” and 
relate.  However, during this time a person living with HIV continues to have a 
relationship with his illness and their behaviors, outlooks, and identity continue to be tied 
to that relationship.  The gaze, thusly, reconstitutes itself and the patient becomes the 
“owner” of the gaze. Second, with the assistance of modern technology, which Foucault 
could not have anticipated, medical knowledge has been democratized, namely through 
the internet.  The “doctor” is no longer the sole holder of information, including 
anticipated symptoms, treatment options, etiology, and lifespan of the pathogen.  Patients 
are, often, more able to access and interpret for themselves this information and make 
judgments independently from their healthcare provider.   
This theoretical paradigm has methodological consequences for data collection 
and interpretation.  Methodologically, I have drawn from the work of Arthur Kleinman 
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and collected illness narratives from my research participants.  These narratives serve as 
tools for the recollection of past experiences and identification of issues and barriers each 
participant faced/faces in his struggle with developing a normative lifeway.  Illness 
narrative approaches to collecting data from people living with HIV have long been a 
staple for anthropological researchers.  For this study, the recollection of past feelings, 
events, successes, and failures especially centered around treatment, offer the raw 
material needed to assess the efficacy of ARV treatment and identify the barriers of/to 
such treatment.  Participant observation in HIV/AIDS-related educational forums 
provided another source of information on the issues faced by people living with 
HIV/AIDS today.  Including both one-on-one interviews and attendance at group events 
allow for a more holistic perspective and comparing data from each site is an interesting 
endeavor in concluding whether my participants are more forthcoming individually or in 
group settings.  Either way, including both sites underscores and takes into account that 
people act and respond differently in divergent settings.  Thus, my methodology is an 
attempt to include a holistic and encompassing perspective in this research. 
Developing a coherent and sound understanding of any illness, from a biological, 
political, social, and economic perspective, is a monumental challenge.  However, the 
myriad complications that HIV/AIDS presents because of its lack of predictability, sexual 
transmissibility, stigmatizing effects, and the social and political instability it leaves in its 
wake only further contribute to those challenges.  Anthropological theory and methods 
offer a unique opportunity to understand how and why the biological and clinical 
manifestations of HIV/AIDS lead to social, political, and economic inequality, 
specifically regarding access to and utilization of ARV treatment.  Furthermore, the 
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effects of that treatment on the perceptions and understandings of those living with the 
illness have the ability to offer insight into more than simply the biomedical benefit of 
ART.  A cost/benefit analysis of ART, from a psychological, biological, social, cultural, 
economic, and personal standpoint has the potential to validate or invalidate the 
continued funding of ARV treatment for those in need, by governmental and private 
entities.  It is my hope that through this research it will be shown that ART has more than 
physical benefits and those benefits may include reducing HIV/AIDS-related stigma, 
using the mind/body connection to incite increased levels of healing and health than ART 
may alone, and allowing people to return to normative lifeways, which has the potential 
to increase economic productivity and contribute to the success of future generations.  
While these may be lofty goals, these idealistic macro-level benefits have substantive and 
concrete implications on the “ground.”  It is these “real world” applications which will be 
highlighted throughout the following pages because, it is my belief that real change and 
progress begin at the level of the individual.     
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Chapter 2 
“Most people have a 1987 view of AIDS and this is 2008:” 
Background. 
 
The HIV/AIDS epidemic has transformed from a sub-population specific virus to 
“perhaps the greatest challenge of our age and our generation” (Kofi Annan 10/10/05) in 
the short span of 25 years: from first being recognized as Gay-Related Immunodeficiency 
Syndrome (GRIDS) in 1981 to now more than 40 million people living with HIV/AIDS 
in the world and 3.1 million people dying from the illness every year.  The mechanisms 
behind the enormous growth in prevalence and mortality of this fatal virus cannot be 
easily or succinctly summarized and has attracted the best minds in public health, health 
policy, humanitarian aid, and government.  However, both the specific etiology and 
epidemiology of HIV/AIDS play large roles in creating the problems faced by the global 
public health community and help explain the astonishingly rapid pace at which 
HIV/AIDS has become the major global health challenge of the 21st century. 
 The first recorded cases of what we now know as AIDS were documented in New 
York City in 1981 because of the onset of rare “opportunistic diseases” which generally 
attack immuno-depressed individuals.  Because of the confines of these rare cancers and 
strains of pneumonia to gay men and because there was no actual evidence of anything 
except immuno-suppression, the cause and transmission of AIDS was obscured.  It was 
not until a year later, when these symptoms were also being reported in hemophiliacs and 
a few women, that the CDC and others identified sexual and blood transmission as 
possible mechanisms.  Furthermore, it was not until 1983 that the retrovirus which causes 
AIDS was isolated and researchers could begin studying it.  Meanwhile, AIDS had 
 8 
appeared on every inhabited continent, in over 51 countries.  By 1985 AIDS had truly 
become a worldwide pandemic spreading rapidly and with no effective treatments 
available.  The first drug approved to combat the effects of AIDS was azidothymidine 
(AZT), in 1987, but at $10,000 per patient a year it was prohibitively expensive and not 
widely available.  It was also in 1987 that a general consensus emerged that the virus, 
HIV, actually led to the syndrome, AIDS.  In 1993 the CDC expanded its definition of 
what constitutes a case of AIDS and the caseload in the United States spiked 111% in one 
year (Castro et al. 1992).  In the years following the expanded definition of AIDS by the 
CDC, many epidemiological reference points shifted leading researchers to a much 
clearer picture of the actual state of the epidemic, especially in the United States.  In 
1995, with the new CDC definition, AIDS and AIDS-related sicknesses became the 
leading cause of death for 25-44 year olds and in 1996, for the first time, the number of 
cases among African-Americans exceeded that of white Americans (Castro et al. 1992).   
This drastic shift in the demography of groups affected by HIV/AIDS most likely 
brought the surveillance community closer to understanding the actual representation of 
HIV/AIDS in the United States and opened a window for public health prevention and 
treatment efforts to expand from targeting traditionally “at-risk” populations into a much 
broader audience.  This transformation was significant in targeting African-Americans, 
Hispanics, and women, especially as the risks associated with heterosexual sex were 
becoming more apparent.  Today the sub-population with the highest rates of infection in 
the United States is African-American women and cases among women, in general, have 
tripled since 1986.  Of women affected by HIV/AIDS in the United States, nearly 70% of 
them contracted the virus through heterosexual intercourse (NIH 2008). 
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However, 1996 also marked a turning point for the fight against HIV/AIDS with 
the introduction of the first Protease inhibitor medications, which were shown to 
significantly extend the lives of people living with HIV/AIDS.  The United States saw a 
23% decline in AIDS-related deaths in that year and a 42% decline the following year.    
With the new medications entering the market, people with access to those medications 
were living longer and substantially altering the mortality landscape in the developed 
world.  But still, the United States has vast inequalities with regards to who is becoming 
HIV positive.  Just a few years later, in 1999, statistics showed that over 95% of the 
worldwide caseload of HIV/AIDS resided in developing countries and 95% of AIDS-
related deaths also occurred in the developing world.  These data promptly altered the 
scope and direction of the greater public health community to focus on HIV/AIDS as a 
global concern, prompting the United Nations, in 2000, to declare the fight against 
HIV/AIDS “…an international security issue because it threatens social, economic, and 
political structures worldwide” (amfAR 2002).  It was not until quite recently that the 
suite of issues that accompany the devastation of HIV/AIDS was realized; 15 million 
children have been orphaned and countries, such as Lesotho, Botswana, and Swaziland 
dealing with nearly 40% of the population infected.  In sub-Saharan Africa, 75% of cases 
in people aged 15-24 are women (UNAIDS 2006).  These statistics help define the global 
issues faced when dealing with the current state of HIV/AIDS.    
Etiologically, HIV is in a family of viruses known as retroviruses.  Human 
Immunodeficiency Virus creates a response in the body’s immune system when it enters 
the body.  White blood cells are produced to fight off the infection and the virus attaches 
to the attacking white blood cells and uses them to replicate.  This is the first stage where 
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infected individuals feel general flu-like symptoms because of the creation of antibodies 
to fight off the invading virus.  Once the virus has attached itself to enough white blood 
cells those symptoms disappear because the “foreignness” of the virus has disappeared.  
The infected individual then enters an asymptomatic “incubation” period, which can last 
from just a couple a months to over 10 years where the patients’ CD4 cell count stays at 
or above 500 cells/mm2.  Once a patient’s CD4 cell numbers reach 499 cells/mm2 they 
have reached stage 2, where most physicians recommend beginning treatment with 
antiretroviral medications to ward off possible “opportunistic infections” which attack 
because of the immuno-suppressed condition.  Treatment is usually not recommended 
before this because of the possibility of developing a drug resistant form of the HIV 
virus, which would seriously disrupt future options for treatment (Blankson 2005).  The 
CDC issued a statement to this effect in 2001 (amfAR 2002).   
At this point HIV medications can extend the life and quality of life of a patient.  
Currently it is unknown how long ART can effectively keep CD4 cell counts high and 
viral load counts low because of its relatively recent development.  However, many 
people who began ARV treatment in the mid-1990’s are still responding to treatment and 
treatment efficacy is highly variable between individuals.  Furthermore, the relatively fast 
development of new classes and types of ART have created innumerable combinations of 
treatment options.  These multiple combinations allow for treatment options if initially 
prescribed combinations are not effective or become ineffective.  Eventually, however, 
the CD4 cell count will begin to decline leading to increasingly more severe immuno-
suppression.  A suite of illnesses accompany stage 2 HIV status including candidiasis, 
bacillary angiomatosis, and pelvic inflammatory disease (PID) (Moss et al. 1988).  Stage 
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3 begins when CD4 cell counts fall below 200 cells/mm2.  At this point a patient is 
diagnosed with AIDS, regardless of the presence of additional infections or not.  
Furthermore, it only takes one CD4 count below that level to be diagnosed with AIDS, 
rather than requiring two or more.  For this reason, the reported AIDS cases in the United 
States may be slightly skewed, including HIV patients with CD4 counts above 200 
cells/mm2 if they have ever had a count below that.  It has been shown by Hoover et al. 
(1992) that CD4 cell counts can fluctuate, by an average of 44 cells/mm2 due to diurnal 
variation.  However, at this point, especially in patients with CD4 cell counts consistently 
below 200 cells/mm2, an opportunistic disease will eventually set in and the patient’s 
immune system will not be able to combat it.  This degenerative nature of HIV/AIDS is 
one of the most distressful aspects of it.  Similarly, the unknown and highly variable 
incubation period make living with HIV a constant guessing game about when, not if, 
your CD4 cell count will begin to decline (Centers for Disease Control 1992). 
 In addition to the biological realities of HIV/AIDS transmission, there have 
always been political and economic determinants hastening the spread of the disease, 
which have particular relevance for sub-Saharan Africa, with 55% of the world’s 
HIV/AIDS cases.  On a much smaller scale, the United States is grappling with the 
inequalities that are becoming apparent through continued surveillance.  While, until 
recently, there was a trend of a declining number of new cases in the United States, 
African-Americans and Hispanics are an increasingly large proportion of those cases, and 
the progressive rate of women, especially young women, acquiring the virus is alarming.  
There is, however, hope, with the creation and availability of drugs, agreements with 
pharmaceutical companies to offer reduced pricing, and the attention of less severely 
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affected nations and the United Nations on programs and monetary resources to combat 
the pandemic. 
 In the midst of these biological, etiological, and epidemiological discoveries, the 
social science community has been actively involved in contributing to cultural 
understandings of HIV risk, coping mechanisms, and more recently, structural constraints 
facing the effective utilization of testing and treatment options.  Early anthropological 
accounts of HIV/AIDS struggled with the inherent complexity and stigmatizing effect of 
the illness.  Understandably, much of the research was focused on the cultural and social 
stigma facing people living with HIV/AIDS and the testing process.  Glick-Schiller 
argued in 1992, and others had earlier, that groups termed “at-risk” by the public health 
community were done so in order to “exoticize” already socially marginalized groups and 
maintain a sense of impenetrability to HIV among the general population (Glick-Schiller 
1992).  Multi-faceted stigma would then be applied to traditionally “at-risk” populations. 
For example, “gay” and “HIV-positive” came to be equated with each other in the public 
imagination.     
 Another vein of early research focused on the adaptive tasks of people living with 
HIV.  The methods which informed these studies drew extensively on the work of Arthur 
Kleinman and instituted an explanatory model and illness narrative approach to 
understanding the illness.  From the very beginning of the epidemic, social science 
researchers were interested in listening to how people felt, which included resistance to 
hegemonic conceptions of risk and infection (Whittaker 1992), dealing with the 
knowledge of a curtailed life span, and maintaining both physical and mental health 
(Siegel and Krauss 1991).  As McCombie (1986) points out while discussing the impact 
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of the introduction of testing options in America, “In some health jurisdictions that have 
embraced the test, it is viewed as a powerful counseling tool and device for behavior 
modification.  However, the actual behavioral outcome that results from being told that 
one is positive or negative has not been documented” (McCombie 1986: 458).  This point 
illustrates the assumptions and causal weight which was, most assuredly, placed on the 
introduction of HIV testing instruments.  
 Likewise, Glick-Schiller (1992) argues that public health authorities incorrectly 
assumed a static and bounded cultural understanding of traditional “at-risk” groups.  Gay 
and bisexual men, Haitians, and intravenous drug users (IVDU) were, simply, at risk, 
regardless of the behaviors they engaged in or the context in which they found 
themselves (Glick-Schiller 1992).  These groups, she goes on to argue, are not distinct 
and bounded, but dynamic and fluid, moving between each other, informing each other, 
and sharing members with one another.  Furthermore, not all men who have sex with men 
(MSM), Haitians, or IVDU engage in behaviors deemed at risk.  Richard Parker (1987) 
also confronts this issue by concluding that the two prominent models of transmission in 
the 1980’s, heterosexual and homosexual/bisexual, “may well have limited our 
understandings of the disease itself, distorted our perception of its transmission, and, 
perhaps most important, partially obscured its potentially more serious consequences at 
home and abroad” (Parker 1987: 156).  These two models of transmission were tied to 
perceived regional variations in transmission with predominantly homosexual/bisexual 
transmission being observed in developed nations and predominately heterosexual 
transmission in Africa, Latin America, and Asia (Parker 1987).  This paradigm helped to 
concretize the stereotypes of “at-risk” populations and, as Sontag contends in her essay 
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“AIDS and Its Metaphors” (1988), all members of these traditional “at-risk” groups came 
to be conceptualized as HIV positive, whether or not they showed symptoms, engaged in 
“risky” behavior, or exhibited any of the “classic” signs of infection with HIV. 
Certainly, the inclusion of MSM in early “at-risk” group categorizations made 
epidemiological sense at the time, but the usefulness of such categorizations needs to be 
questioned.  The prevailing paradigm, which necessarily associates unassociated 
characteristics with HIV transmission, such as sexuality identity, country of origin, or 
medical condition, needs to be questioned.  A paradigm which focuses on behaviors, and 
the underlying causes of those behaviors, should take its place.  Behaviors, such as 
unprotected sex, needle sharing, and receiving unscreened blood transfusions are the 
causes of HIV transmission, not sexual orientation or birth place or drug use.  As 
Marshall and Bennett contend, “Although the ‘risk group’ idea is useful, in reality all 
people are at relative risk as a result of particular behaviors – their own or others’” 
(Marshall and Bennett 1990: 4).  And while these routes of transmission are the target of 
most interventions today, early public health strategies had already ingrained powerful 
associations between the “at-risk” groups and ubiquitous HIV infection.  So ubiquitous 
are these connections that even the members of those “at-risk” groups are not surprised 
when they are diagnosed, and as Gary, one of my informants, told me, it “made sense” 
that he was HIV-positive.  This consent and unquestioning compliance among 
marginalized populations truly illustrates the hegemonic power that public health 
authorities have in the conceptualization of epidemic disease.  Glick Schiller expands on 
this concept as “the means by which subordinated populations participate in cultural 
constructions that contribute to their continuing subordination” (Glick Schiller 1992: 
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248).  It is clear that my participants continue to be influenced by this public health 
hegemony  
As the biomedical picture of HIV and AIDS progressed, transmission 
mechanisms became clearer, testing procedures advanced, treatment options expanded, 
and the demographic and epidemiologic diversity of the epidemic grew, public health 
officials, and, in turn, the general population could no longer generalize and stereotype 
who became infected and why.  Social scientists began attempting to explain the growing 
inequality of infection, as increasing numbers of people of color, the poor, and the 
socially marginalized were being diagnosed.  The structural constraints of poverty, 
education, language, and access to testing and treatment began to become elucidated and 
public policy soon followed.   
Legislation, such as the Ryan White Act, was passed in 1990, guaranteeing access 
to treatment for all minors and providing supplemental coverage for people whose needs 
were not being met by Medicaid or private insurance (Dept. of Health and Human 
Services, HIV/AIDS Bureau 2008).  Along with access to treatment and testing services, 
the confluence of sex, drugs, poverty, and HIV was becoming increasingly clear.  
Gorman et al. (1997) was one of the first studies to document the deadly combination of 
crystal meth and HIV infection and the resurgence of HIV infection among traditional 
“at-risk” groups, especially MSM.  They contend that, “Gay and bisexual men are of 
particular concern because of their multiple risk factors for HIV infection and 
transmission” (Gorman et al. 1997: 507).  While drug use alone can not be termed a 
structural limitation, in and of itself, Gorman et al. suggest that higher levels of drug 
usage exist among lower socio-economic status (SES) and homeless MSM.  While the 
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causal mechanisms between low SES and drug use are unclear, it has been posited that 
mental illness, such as depression, can influence both factors and that a cyclical 
relationship exists between low SES and drug use, with each contributing to dependence 
on the other (Gorman et al 1997: 509).   
Likewise, Singer and Clair (2003) point to the syndemic nature of HIV/AIDS, 
especially in urban inner-city environments where poverty, drug use, HIV, and a host of 
other illnesses coalesce at the individual and population levels and have direct 
biomedical, social, economic, and political consequences.  They contend that, 
“Ultimately social factors, like poverty, stigmatization, racism, sexism, ostracism, and 
structural violence may be of far greater importance than the nature of pathogens or the 
bodily systems they infect” (Singer and Clair 2003: 428).  According to Singer and Clair, 
the recognition of the syndemic possibilities of the HIV/AIDS pandemic have largely 
been recognized in the last 10 years and have forced a change in the focus of research to 
the biocultural and structural assessments of the illness and the ways in which HIV/AIDS 
interacts with other diseases, cultural models and classifications of illness, and social and 
economic marginalization (Singer and Clair 2003).  This assessment calls for the study of 
HIV/AIDS from a holistic structural, political, economic, social, and historical 
perspective.      
 The study of these structural limitations, which tend to interact with and 
exacerbate each other, perhaps offers the most concrete and coherent possibility of 
benefit to the HIV community.  While U.S. policy has, in many ways, been progressive, 
both domestically and internationally, a greater understanding of the logistical, financial, 
and cultural constraints people face is necessary in order to develop increasingly 
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efficacious and beneficial testing, prevention, and treatment programs.  The United States 
has funded HIV treatment since the early 1990’s through multiple means, including 
Medicare, Medicaid, the AIDS Drug Assistance Program (ADAP), and by subsidizing 
individual local and state programs.  However, the effectiveness of these programs, 
especially to socially and economically marginalized populations, needs to be evaluated.  
Similarly, there remains a substantial population who are unable to access these 
assistance programs.  Many of these people simply fall through the cracks of government 
bureaucracy; the self-employed who cannot afford private health insurance, those unable 
or unwilling to negotiate the confusing government red tape, and those who have private 
insurance but cannot afford increasingly high prescription co-pays. 
The marginalization of traditionally “at-risk” populations is not confined to the 
shaping of the public imagination and public health response. Economic factors that 
shape whether or how someone accesses healthcare, specifically ART, also play a part in 
how marginalized populations are further subordinated.  The epidemic of runaway gay 
youth, such as Jake, one of my informants, as evidenced by the numerous support 
agencies devoted to this particular topic, creates a precarious situation of economic 
instability and, in many cases, the loss of sexual agency.  Many homeless gay youth turn 
to commercial sex work and drug use as means to economic and emotional support and 
stability.  In a study conducted in 1993-1994, Clatts and Davis (1999) found that nearly 
35% of their sample of homeless youth in New York City identified as gay or bisexual, a 
number they contend is probably under-representative of the actual prevalence of 
homeless gay youth (Clatts and Davis 1999).  They also note that prostitution and illegal 
drug use are staples of both income and recreation for many homeless youth.  Multiple-
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partner unprotected sex was significantly associated with being gay or bisexual (p<.001) 
in their population and the ramifications for HIV infection risk are clear (Clatts and Davis 
1999).  In this example a disproportionate number of homeless youth identify as gay or 
bisexual and that identification makes them more likely to engage in behaviors deemed 
“high risk” by public health authorities.  It is clear that the structural limitations of 
discrimination and social marginalization and the possibilities for action, based on 
personal agency, are intertwined and shape the situations available to homeless gay youth 
in tandem; economic marginalization and a decrease in sexual agency. 
Another area where the line between what is structural and what is agential is 
blurred is the decision to forgo public funding, namely Ryan White based programs, even 
when exclusive use of private insurance represents a financial hardship for the person 
living with HIV/AIDS.  While burdensome prescription co-pays could be offset by 
federal assistance programs, these programs are often conceptualized as the easy way out 
or available to people who do not see themselves as the “type” of person to utilize 
government assistance programs.  Welfare recipients carry with them a certain stigma 
and the aversion to accepting Ryan White based funding could be viewed as an attempt to 
reduce the stigma already felt by people living with HIV/AIDS (Bullock 1999).  As such, 
people with private insurance have a choice, mediated by personal agency, to accept or 
forgo such funding, if they qualify for it.  However, this choice must be contextualized 
within the economic realities of each person and the structural constraints imposed by 
such limitations.  It is, therefore, a choice based on a synergy of factors, including 
personal agency and structural limitations, which inform such decisions.   
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Obviously, more needs to be done on the domestic front to develop new 
innovative programs with greater depth and scope, in terms of whom they provide for and 
the services they provide.  One positive change, occurring as we speak and continuing 
over the next few years, is the conversion to generic drugs in the U.S.  This process 
greatly reduces the cost, not only to the consumer, but to insurance companies and the 
government who are buying drugs from the pharmaceutical companies.  These positive 
changes offer the opportunity to innovate in the future, as long as the supporting research 
and political will are present.         
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Chapter 3 
“A second coming out:” The Clinical and Reflexive Gaze. 
             
 
The theoretical perspectives which inform this research emanate from Michel 
Foucault’s discussion of biomedicine and the clinical gaze and from Arthur Kleinman’s 
concepts of the explanatory model and the illness narrative.  These two independent, yet 
compatible bodies of work are well suited to developing an understanding of how people 
living with HIV/AIDS define their relationship with the illness and negotiate the 
obstacles, both structural and personal, which stand in the way of reclaiming “normal” 
lifeways.  Although Foucault’s clinical gaze (Foucault 1973), both a producer and by-
product of hegemonic biomedical control, continues to impact the clinical experience, the 
biological realities of HIV and the technological advances of post-industrial society have 
lead to a re-structuring of the power relationships which formerly directed the clinical 
experience.  Kleinman (1988), taking account of this phenomenon, has called for 
clinicians to take seriously the explanations and accounts of causation that their patients 
offer, in effect to elicit illness narratives from their patients.  This power shift has not left 
healthcare providers without authority, but has chipped away at the hegemonic control of 
biomedicine and traditional clinical teaching.  Homeopathic, complementary, and new-
age therapies are becoming increasingly popular and legitimate as patients seek out their 
own explanations of causation and illness.  Healthcare providers and insurance 
companies are forced to add legitimacy to these treatments in order to maintain their own 
hegemony over an increasingly non-Western healthcare sector.  Kleinman, then, 
expounds, although not explicitly, on the reversal of Foucault’s clinical gaze by 
addressing the innate possibility for patient agency within the clinical setting.  By 
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encouraging the patient to talk about their illness one is also encouraging them to 
consciously think about and develop notions and authoritative knowledge about their 
illness.     
In The Birth of the Clinic: An Archeology of Medical Perception, Michel Foucault 
(1973) develops the idea of the clinical gaze, which he posits is both a literal and 
metaphorical gaze which conveys meaning from the patient, or more accurately the 
patient’s symptoms, to the doctor.  The doctor can then assess the symptoms using his 
exclusive knowledge in biomedicine to treat the patient.  As Foucault understands it, the 
clinical gaze is possessed solely by those who have undergone biomedical training and 
are educated in the clinical and environmental causes of disease.  It is intentionally 
obscured from the patient through the specific educational requirements of biomedicine 
that are relegated to exclusive institutions inaccessible to the lay population, the 
standardization and institutionalization of biomedicine, such as board certification, and 
the development of a particular “language” to identify disease, symptoms, and treatment.  
In fact, Foucault argues that the patient becomes the disease in eyes of the medical 
professional, saying, “The patient is the rediscovered portrait of the disease; he is the 
disease itself, with shadow and relief, modulations, nuances, depth; and when describing 
the disease the doctor must strive to restore this living density…” (Foucault 1973: 15).  
With the doctor conceptualizing the patient as simply an embodiment of disease, the 
patient loses agency and the ability to contribute to the diagnosis and treatment process 
and become an active participant in his/her own lived experience.  Foucault argues, 
however, that this disassociation of the patient from his/her disease is a side effect of the 
hospital and clinical teaching paradigms.   
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These two spaces force doctors to concentrate on disease by the nature of their 
purpose, which is to instruct students about disease and have the “[tendency] to prefer 
those cases that have a high instructive value” (Foucault 1973: 59).  An important 
distinction here is that between patients and cases.  When doctors assess cases they are, 
often, addressing the social and historical causations of disease and treating the whole 
person, namely treating illness.  Hospitals are a space devoted to treating illness, not 
disease, and although this medical distinction had not been made yet at the time of 
Foucault’s writing, he understood the difference in the context of how spaces were used, 
namely the hospital versus the clinic.  Although it seems that Foucault is often implying 
the greater existence of patient agency in the hospital, this point is never explicitly stated.  
He does say, however, that “in the hospital, the patient is the subject of his disease, that 
is, he is a case; in the clinic, where one is dealing only with examples, the patient is the 
accident of his disease, the transitory object that it happens to have seized up” (Foucault 
1973: 59, emphasis in original).  Here, Foucault is concretizing the difference between 
hospital and clinic, disease and illness, and patient and case.  
 All of these factors are informed by the clinical gaze, which is always in operation 
in both hospitals and clinics.  As Foucault describes it, the clinical gaze is a conduit of 
both information and meaning.  The diseases, which are signified to the doctor by their 
symptom manifestations, have both biomedical and cultural significance to the doctor and 
patient.  As Stein (1986) contends those significances and meanings are then interpreted 
by the biomedical professional to fit within their own worldview and cultural 
understandings.     
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Foucault saw the clinical gaze as both hiding and illuminating “truth” at the same 
time.  This seemingly paradoxical statement is reconciled because in Foucault’s work 
truth is not just one fixed reality, but an ever expanding field of perception and 
knowledge.  Therefore, the gaze is superimposed on top of truth because it acts as a 
conduit between what one sees, what one knows, and how one speaks.  In relating this 
concept to medicine, Foucault wrote of the difference between symptoms, signs, and 
disease.  Symptoms and signs are tools used to relate the perception of disease to the 
doctor.  Because one cannot actually see disease, one must rely on the 
physical/perceptual manifestations of disease in order to ascertain the effects on the body 
and mind.  Because symptoms and signs are directly observed, they are what add to 
medical knowledge, not disease itself (Foucault 1973: 5).  Therefore, because what a 
doctor observes is translated into knowledge, disease becomes the object of the gaze and 
the patient becomes nothing more than a positive support mechanism for disease.  The 
doctor’s role has thus been cemented as biologically centered, rather than socially 
centered.   
 Furthermore, the clinical gaze is confounded by the use of language to convey 
meaning and knowledge in a clinical setting.  How one talks about medical phenomena in 
turn creates those phenomena.  More specifically Foucault writes, “There is disease only 
in the element of the visible and therefore statable” (Foucault 1973: 95).  Disease 
becomes the interpretation and perception of symptoms which are seen by the doctor, 
related by the patient, and taught to the medical student.  Symptoms become bound to 
disease and are therefore signified by it; however, the purpose of assessing symptoms is 
to signify disease.  Symptoms become both signifier and signified which lends them a 
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certain particularism which disease is lacking.  They are perceived as limited in number 
and scope and vary only in time, intensity, and combination (Foucault 1973: 101).  Once 
these relatively few symptoms are identified and understood, they add a transparency to 
disease and the patient becomes subordinate to the pathological facts he embodies which 
the gaze can observe and verbalize.   
 The authoritative knowledge which the clinical gaze conveys has been 
reinterpreted to include not only the biomedical knowledge of the healthcare professional, 
but also a patients own understandings of illness and physical manifestations of disease 
as a social marker as authoritative knowledge bases.  Asha Persson (2005) writes of how 
the clinical gaze becomes the social gaze when HIV infection becomes visible due to the 
introduction of ART and its related side effects.  ART can often cause a condition called 
lipodystrophy in which fat deposits in the body are reconstituted to cause visible fat 
deposits in the belly and back of the neck and the loss of fat in the arms, legs, and 
buttocks.  This condition has become a marker of HIV status among the population she 
studied in central Sydney and its presence imparts information and meaning from the 
individual to the larger community.  Thus, the same signs and symptoms that Foucault 
articulated as informing the medical professional are now informing the general populace 
within the context of the post-industrial Western world where information about ART 
and its side effects are easily accessed and widespread.  In my research I have found what 
I have called the reflexive gaze, in which the patient must make sense of their own 
disease.  This process is central to the creation of an identity, or identities, corresponding 
to their illness.  Foucault’s framework of only being able to “observe” the physical is 
problematized when applied to a disease like HIV where there are few, if any, physical 
 25 
manifestations through much of its trajectory.  The event of diagnosis, along with 
subsequent events, which may or may not be perceived as directly related to serostatus, 
all contribute as outcome variables to the eventual creation of a grouping of identities 
used to interact both with the disease and within social settings.  As discussed in more 
detail in the literature review section, many people have studied how individuals cope 
with HIV and explain their own illness experiences.  However, to my knowledge, no one 
has characterized these self-reflexive processes using a Foucauldian paradigm.  
Conceptualizing how a person understands their own illness as an informative and 
meaningful transfer, or transition, of knowledge through the use of a reflexive gaze 
continues to be of importance to the fields of medicine and social science.     
 In addition to the clinical gaze, Foucault espoused a theory of truth in relation to 
illness which, in his view, allowed him to systematically and objectively analyze 
historical documentation.  When Foucault wrote about truth he did not mean “Truth,” but 
increasingly complex layers of perception.  “For Foucault, fields such as psychiatry and 
biomedicine are best understood as ‘cultural systems’ that offer different claims to truth.  
The evidence they amass, and the understandings they promote are not ‘facts’ or ‘truths’ 
in any simple sense, but social products linked to the power of the profession” (Parker 
and Aggleton 2003: 17).  The method he utilized, what he called “archeology,” was an 
attempt to ascertain truth not through discourse, which would only complicate the already 
muddled conversation, but through systematic analysis (Dreyfus and Rabinow 1982: 14).  
This archeology was meant to add to the discourse by analyzing the innate dialogue 
which naturally emanates from all social institutions (Dreyfus and Rabinow 1982: xxiv).  
He is then able to treat discourse as an object of analysis and transcend the existing 
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debates about the “truth” of the discourse. 
 The Birth of the Clinic was Foucault’s most explicit example of structuralism 
because of his analysis of social institutions, such as the clinic, as “autonomous systems 
of discourse” (Dreyfus and Rabinow 1982: xxiv).  He also refers to discourse, which he is 
attempting to study, as a system governed by strict and replicable rules (Dreyfus and 
Rabinow 1982: xxiv).  He showed that medicine is actualized and made real only through 
perception and that how doctors used that perception to diagnose and understand disease 
was arbitrary and subject to the idealization of biomedicine in Western intellectual 
tradition.  Society had become medicalized, and thus enslaved to the limits of categorical 
accounting of patients and disease.  Innumerable iterations of cases and great diversity in 
experience became hallmark traits of the clinic (both clinical medicine and medical 
education) (Foucault 1973: 101).  The new truth of medical perception became 
institutionalized in collective consciousness.  That is to say that a dominant medical 
“knowledge” permeated society.  This knowledge was controlled and amended by 
clinical medicine and was given the power of a social fact by those who adhered to the 
theory of biomedicine.  It is this collective consciousness which Paul Farmer (1999) 
refers to as cultural models (Farmer 1999: 166).  Although these concepts might not be 
perfect synonyms, they both are meant to describe how population level understandings 
of disease and illness function and biomedicine, in a U.S. context, contributes to the 
creation of these cultural models.    
Foucault’s idea about collective consciousness has thus been interpreted to mean 
how a population or community constructs and renegotiates notions about what disease 
is, how to treat it, and how to behave toward it.  The cultural models serve as a “baseline” 
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understanding for how a disease is viewed in the context of a particular culture.  A 
cultural model of disease becomes truth, albeit dynamic and constantly updated, through 
a population’s local experiences which inform their developing notions about who gets it 
and how they get it (Farmer 1999: 168).   
While Foucault was writing about illness from a decidedly structural and systemic 
perspective, his concepts are echoed from a more psychological and personal perspective 
through the work of Arthur Kleinman.  Although Kleinman’s work is often 
conceptualized from a methodological standpoint, as I have also largely done, he makes 
key theoretical insights to the study of illness identity.  Kleinman recommends important 
advancements in the practice of clinical biomedicine with the development of the 
explanatory model (EM) and the use of illness narratives to address the patient’s concerns 
and assist in the physician’s diagnosis of illness.  These methods, then, have the effect of 
increasing patient agency within a clinical context and reducing any confusion that may 
exist between the physician and patient.  By including the patient’s perspective in the 
overall diagnosis schema, it is hoped that interpersonal, cultural, and linguistic 
differences can be reconciled.  Supporting this increase in agency is an important step in 
the collection of illness narratives and can greatly alter the ways in which a person 
interacts with their own illness.  This point is especially important to this study because 
increased patient agency is also a key factor to determining access to ART within a 
context of a sophisticated and often confusing health care system.   
  The concept of illness narratives not only necessitates the inclusion of the 
patient’s perspective in diagnosis and treatment schemas, but alters the direction of 
authoritative knowledge and chips away at the hegemonic control of biomedicine.  
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Kleinman develops a paradigm in which a patient’s relationship with and understandings 
of their illness are important tools used by both the healthcare provider and patient, 
himself.  While Kleinman focuses on the outcomes of this patient-illness relationship for 
the healthcare provider, the act of developing this relationship is an important component 
to how and what the patient feels is important to relate to the healthcare provider.  The 
analysis of this process, from an anthropological perspective, is, thus, a key element to a 
holistic understanding of illness and lived experience, from the patient’s point of view.  It 
is this process through which the reflexive gaze can be understood as a conduit of 
meaning between the illness and the patient.  From the moment of diagnosis, or even 
earlier is some cases, a patient must make sense of his illness through the lens of personal 
experience and standing cultural models.  While these cultural models of illness may 
inform the general population, and to some extent, the patient himself in assigning 
meaning to a particular illness, the lived experience of illness, diagnosis, symptom 
awareness, clinical experience, and treatment efficacy, play a large role in how one deals 
with, assigns meaning to, and develops understandings about what is occurring within 
their body and the eventual outcome of their experience.  These two conduits of meaning, 
the social gaze and the reflexive gaze, create reference points for interpretation of the 
illness experience.   
 To a large extent, especially in the case of HIV/AIDS, stigma has played an 
historically important role in the development of understanding the illness, both among 
the general population and individual people living with HIV/AIDS.  While Goffman’s 
classic definition of stigma as a discrediting characteristic (Goffman 1963) applies, 
generally, to HIV/AIDS, much more specific and timely work has been done in response 
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to the HIV/AIDS epidemic.  Richard Parker and Peter Aggleton offer a conceptual 
framework for understanding HIV/AIDS-related stigma as a “reproduction of social 
difference” (Parker and Aggleton 2003: 13).  They argue that stigma can be read as 
reproductions of gender, race, class, and sexual inequalities.  An important concept that 
Parker and Aggleton have contended, and that I am reasserting here, is that previous work 
done on HIV/AIDS-related stigma, “has encouraged highly individualized analyses in 
which words come to characterize people in relatively unmediated fashion” (Parker and 
Aggleton 2003: 14).  This “personalistic” analysis of stigma has imposed not only the 
identification of stigmatized on people living with HIV/AIDS, but also imposed the value 
and type of relationships, which stigma is understood to devalue.  The imposition of 
value by the researcher, as well as, in many cases, internalized judgment, has significant 
outcomes on data collection.  Although it has long been a mantra of anthropological 
fieldwork to be cognizant of the researcher’s influence on the study population, this 
realization is often more difficult to put into practice than it is to enunciate.   
 There is a large body of literature on stigma, HIV/AIDS-related stigma included, 
which frames the concept as a means of social control.  Stigma acts as a mechanism to 
“otherize” those possessing the stigmatizing trait.  By forcing those with the trait, in this 
case people living with HIV/AIDS, out of the mainstream, social and economic 
marginalization of that population is maintained.  This process is cyclical in nature, with 
the subjugation of trait-carrying populations as a result of and resulting from possessing 
the characteristic.  The stigmatized group is unable to access the appropriate support 
mechanisms and, in the case of infectious disease, the implication is the relegation of the 
illness to subjugated and stigmatized groups.  In the case of the HIV/AIDS epidemic in 
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the United States, traditionally stigmatized groups, such as MSM, IVDU, and certain 
immigrant groups who exhibited high rates of infection from the beginning of the 
epidemic, were further marginalized in an attempt by the general population and, as some 
would argue (Glick-Schiller 1992), public health officials to create a belief of 
impenetrability to HIV/AIDS among non-marginalized, or socially elite, groups.  Parker 
and Aggleton argue that to distance ourselves from such a view we must consider: 
[A] new emphasis on stigmatization as a process linked to competition for power 
and the legitimization of social hierarchy and inequality, highlight[ing] what is 
often at stake in challenging HIV and AIDS-related stigmatization and 
discrimination.  It encourages a move beyond the kinds of psychological models 
and approaches that have tended to dominate much of the work carried out in this 
field to date – models which all too frequently see stigma as a thing which 
individuals impose on others.  It gives a new emphasis to the broader social, 
cultural, political, and economic forces that structure stigma, stigmatization, and 
discrimination as social processes inherently linked to the production and 
reproduction of structural inequalities  (Parker and Aggleton 2003: 18-19).   
           
Viewing stigma as not just a psychological or emotional barrier to social equality, but as 
a process and mechanism for political, social, and economic control and subjugation is an 
integral component to the Parker and Aggleton framework.  Overcoming that subjugation 
by addressing the structural forces reproducing inequality is a necessary step in, not only 
reducing HIV/AIDS-related stigma, but also in increasing the benefit of HIV/AIDS 
testing, treatment, and support entities. 
 What Parker and Aggleton are proposing is an emphasis on the structural 
constraints, or structural violence, which breed inequality and stigma.  Paul Farmer has 
been a leading voice in anthropology, public health, and clinical medicine calling for the 
concentration of academia and resources on the alleviation of the root causes of 
inequality.  He, and others, have called for the development of critical medical 
anthropology, “the application of political economy and world systems theory to the 
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domains of sickness and health care” (Scheper-Hughes and Lock 1986: 137).  A critical 
approach to the field takes the culturally deterministic and culturally bound notions of 
health and illness and puts them in political, economic, and historical perspective.  This 
study is an attempt to continue that tradition and develop a holistic picture of the state of 
access to ART in the United States today.  While Farmer, as a physician/anthropologist, 
has always begun from a different set of assumptions than the traditional anthropologist, 
he has continued to assert the benefit and importance of anthropological research to the 
study of illness.  In his Pathologies of Power: Health, Human Rights, and the New War 
on the Poor he makes an eloquent plea for the reinstatement of the concept of “bearing 
witness.” He contends that the socially and economically marginalized are conditioned 
into silence by the weight of structural violence; it is not that they are unable to speak for 
themselves or could not make sense out of their plight, but “members of any subjugated 
group do not expect to be received warmly even when they are sick or tired or wounded” 
(Farmer 2005: 25).  As anthropologists, we bear witness to this suffering and attempt to 
relay it to a wider audience - to expose the injustice and inequality in the world.  But 
again, Farmer is wary of this anthropological convention, saying, “to be honest, writing 
of the plight of the oppressed is not a particularly effective way of assisting them” 
(Farmer 2005: 26).   
A praxis approach to anthropological research development is needed in order to, 
not only document, but alleviate the suffering and inequality we, as anthropologists, 
contend with in our research.  This is an important point from both a theoretical and 
methodological perspective.  Praxis anthropology is an attempt, not only to develop and 
test theoretical possibilities, but also to ensure that social justice is maintained or 
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promoted (Kozaitis 2000).  In the case of HIV/AIDS in the United States, vast 
inequalities exist, not only in who is becoming infected, but who is receiving optimal 
healthcare and treatment.  When put into political-economic perspective, many of these 
inequalities can be attributed to structural violence.  Although structural determinants of 
increased risk for infection is extremely difficult to prove, it is no accident that people of 
color, the poor, and socially marginalized have the highest rates of infection in America, 
and throughout the world.  The intricate webs of poverty, drug use, intravenous and other, 
and lack of access to healthcare education, testing, and treatment spin a morbid and 
disturbing tale of HIV infection with little possibility of management.  The praxis 
anthropologist has an obligation, not only to expose these inequalities, but also to use the 
data and conclusions from their research to the benefit of the community they are 
working in.  While the explicit implications of this research will be discussed in depth in 
the conclusion, it should be noted now, as a theoretical point, that I am employing both a 
critical and praxis medical anthropological paradigm.  From the cerebral ruminations of 
Foucault to the methodological applicability of the work of Kleinman, Farmer, and 
Kozaitis, the theoretical underpinnings supporting this research are focused on the effects 
of inequality and subjugation on the creation of illness-related identities, specifically, in 
regards to HIV/AIDS and access to ARV treatment.                       
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Chapter 4 
“HIV isn’t a gay thing but if you were straight this wouldn’t have 
happened:” Literature Review: 
 
According to the National HIV Prevention Conference (2005) an estimated 1.1 
million people were living with HIV/AIDS in the United States in 2003 and over half a 
million people have died of AIDS since the beginning of the epidemic.  While funding 
within the United States for providing antiretroviral access could be considered an 
exemplar for other countries, there are still strikingly disconcerting epidemiological 
trends which are woefully under-nuanced in the literature.  There are only two main 
routes to reliable and cost-effective access in the U.S.: private insurance and government 
subsidies such as Medicare and Medicaid.  In addition to these more dependable 
frameworks there are also multiple non-profit and philanthropic organizations which 
distribute either antiretrovirals directly or finance private health insurance for those who 
can not afford it.  At the head of these groups is a government organization, the AIDS 
Drug Assistance Program (ADAP).  However, there are multiple issues restricting the 
availability of these resources, including limited funding, perceptions of stigma and 
discrimination, and logistical limitations of geography and access.  Thus, access to 
antiretrovirals is still an important and contested issue in the United States with multiple 
layers of inequality.  Unpacking and understanding how access to antiretrovirals informs 
a person’s understandings of their seropositive status can be an important component to 
asserting the significance of continued and increased funding to government and non-
profit organizations providing free or subsidized antiretroviral access or insurance 
coverage to those who would otherwise not have such access. 
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Even though these large and daunting issues continue to surround the American 
epidemic, anthropologists, public health officials, the media, and the popular imagination 
have turned their rather considerable attention to the pandemic facing the developing 
world in recent years.  Anthropological attention to HIV/AIDS research began in the first 
years after the “latest and most deadly venereal scourge” (Kleinman 1988; 84) was 
discovered and isolated and by 1988 an already large and quickly growing body of 
literature had been amassed.  This new literature focused mainly on domestic concerns, 
and as epidemiologic studies began to surface, on specific sub-group populations.  These 
sub-groups, termed “at-risk” populations, tended to include what was then termed gay 
and bisexual men, intravenous drug users (IVDU), and recent immigrant groups, 
especially from Haiti.   
These studies, of which I have selected a small sample to discuss in more depth, 
tended to focus on coping mechanisms and the lived experience associated with a 
positive serostatus diagnosis.  In “Living with HIV Infection: Adaptive Tasks of 
Seropositive Gay Men,” Siegel and Krauss (1991) identify three challenges that confront 
people living with HIV: “dealing with the possibility of a curtailed life span, dealing with 
reactions to a stigmatizing illness, and developing strategies for maintaining physical and 
emotional health” (Siegel and Krauss 1991; 17).  By 1991, when this article was 
published, the first generation of antiretroviral (ARV) medication was widely available in 
the developed world which had allowed HIV to be reconceptualized as a chronic illness 
(Chaison 1990; Coates 1990; Cotton 1989; Mayer 1989; Piot 1987; Redfield and Burke 
1988).  Although the proper use of ARV therapy can extend the lives of people living 
with HIV/AIDS, the disease still has an unpredictable trajectory and this uncertainty can 
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cause patients to discontinue investing in their future and attempt to complete life goals 
urgently (Siegel and Krauss 1991; 21).  This, and other studies, set an important 
precedent for using unstructured interviews and an illness narrative approach to the study 
of HIV. 
In a more recent attempt to discuss life trajectory and changing perceptions of 
quality of life, Bloom, in his article, “’New Beginnings’: A Case Study in Gay Men’s 
Changing Perceptions of Quality of Life during the Course of HIV Infection,” illness 
narratives were elicited, leading to life history accounts and how HIV related to the 
overall “psychocultural expression of the self” (Bloom 2001: 41).  Bloom arranges the 
results of these life histories into thematic groupings, including survival, reciprocity, 
appreciation, and average life.  He contends that the theme of survival is, by far, the most 
numerous which is characterized by overcoming obstacles and hardships.  These themes 
must then be understood within the context of the personal, situational, social, and 
historical (Bloom 2001: 48).  Again, adding this context to what people say and how they 
act is a crucial component to understanding HIV/AIDS and personal and social responses 
to it.  While Bloom includes a discussion of cultural values, and how they shape the life 
histories of his research participants, as the context for understanding his thematic 
arrangements, the structural forces which shape(d) the narratives of his participants are 
ignored.  He offers lip service to power relationships and their effects on understandings 
of illness but the concrete mechanisms of social and economic marginalization are not 
discussed.  This article adds to the large literature which, “has been on the perceptions of 
individuals and the consequences [of] (sic) these perceptions for social interactions.  
Much work has tended to focus on stereotyping rather than on the structural conditions 
 36 
that produce exclusion from social and economic life” (Parker and Aggleton 2003: 15). 
Stigma has long been conceptualized as both a structural and psychological 
impediment to prevention and treatment efforts for HIV/AIDS.  McCombie offers an 
early example of how the introduction of the ‘AIDS’ test worked to both misrepresent 
who is at risk for acquiring HIV/AIDS and function as an unwarranted measure to reduce 
transmission.  McCombie shows, through data collected through participant-observation, 
that public health and healthcare workers further reinforced stigma targeted at traditional 
“at-risk” populations by assuming their risk behaviors were more likely to result in 
infection than their “less at-risk” counterparts.  Furthermore, because McCombie 
contends that the ‘AIDS’ test was conceptualized as a “magic bullet” to interrupt 
transmission of HIV, it was seen as a behavior modification tool.  Similarly, Glick-
Schiller (1992) argues that public health has assumed the behavioral outcomes of HIV 
testing and treatment among traditionally “at-risk” populations and those assumptions 
come with little research to support their claims.  In fact, McCombie writes, “the actual 
behavioral outcome that results from being told that one is positive or negative has not 
been documented” (McCombie 1986: 458).  While these issues have been better studied 
in the years following McCombie’s article, her point illuminates the general need for 
more qualitative and contextual research on the socio-cultural effects of testing and 
treatment on individual and collective behavioral outcomes. 
Another article, with particular relevance to my own study is “Living with HIV: 
Resistance by Positive People.”  In this article (1992), Andrea Whittaker attempts to 
show that activism by people living with HIV/AIDS is a form of resistance to the 
hegemonic discourse surrounding the illness.  She posits that HIV activists have 
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developed several strategies through which they redefine their relationship with their 
illness in a positive manner, rather than utilizing popular ideas about HIV, which tend to 
construct it in a negative light.  These strategies include “the inversion of AIDS 
metaphors; the redefining of being HIV antibody positive as a stage in a disease process, 
not a terminal condition; and an active engagement with their condition” (Whittaker 
1992; 385).  These strategies were developed to give a voice and agency to the most 
important stakeholders in the game, those living with HIV/AIDS.  Whittaker elicits 
explanatory models from her subjects in order to understand how they think about and 
react to their illness, which was an important methodological breakthrough for the early 
1990’s.  While I believe that Whittaker was influenced by the en vogue notion of 
resistance that was so pervasive at the time, her work using qualitative methods in order 
to attempt to understand the patient’s relationship with their illness added to the growing 
literature of qualitative HIV research at the time and is worthy of note. 
As time progressed, the reliance of the public health community on “culture” as 
an explanatory mechanism began to be called into question by the anthropological 
community.  Glick-Schiller (1992) offers an important and timely discussion and critique 
of the ways in which the concept of culture can be misinterpreted by the public health 
sector when defining “at-risk” groups in terms of acquiring HIV.  She argues that public 
health officials often take a rather simplistic view of culture, assuming that each “at-risk” 
population has distinct and bound cultural practices unique to its members.  Thus, the 
implicit assertion is that these groups never overlap or mix and that cultural behaviors are 
universal for a given “at-risk” population.  While these assumptions may make 
epidemiological studies easier by grouping individuals using demographic and lifestyle 
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information, they do not capture the subtle and complex ways that “culture” can be 
dynamic, overlapping, and fluid between and within populations. 
 One of the most important points Glick-Schiller mentions is the need to address 
issues of structural violence.  She contends that although a public health focus on culture 
as an explanatory technique is beneficial in principle, the definition of the concept is 
applied only simplistically, with often detrimental consequences.  On the other hand, an 
anthropological conception of culture is much more nuanced, focusing on the collective 
behaviors of groups of individuals rather than generalizations about populations.  This 
subtle distinction has profound implications.  While Glick-Schiller does not use the term 
“structural violence,” she is referencing a need to assess the structural reasons which lead 
to risky behavior (Farmer 1999).  Issues of poverty, racism, classism, and power lead, 
both directly and indirectly, to what are now termed “risky” behaviors.  Paul Farmer was 
one of the first anthropologists to articulate the extreme influence these factors can have 
on individual and population level behaviors in relation to health and illness (Farmer 
1999).  While the anthropologist is most interested in the collective and the 
epidemiologist on the population level, these two perspectives can, and should, inform 
each other.  These forces of power, racism, and poverty manifest themselves, in similar 
and different ways, at both levels.  Another of Glick-Schiller’s main arguments is to point 
out the hegemonic constructions of AIDS “risk groups.”  She contends, and I believe 
accurately, that risk groups, which can have some basis in biological and epidemiological 
reality, are essentially a way to define those with HIV/AIDS as the “other.”  Again, to the 
public health community, those who are members of “risk” group populations are at risk 
because of their race, gender, or lifestyle, and not because of the behaviors in which they 
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engage.  Much like Glick-Schiller’s critique, more recent anthropological articles have 
engaged the public health community in debates over a myriad of issues including the 
development of culturally appropriate prevention and treatment programs (Smith 2003; 
Abadia-Barrero and Castro 2006) and unmasking the false dichotomy between prevention 
and treatment in public health (Onjoro Meassick 2007).   
 Another important issue beginning to crystallize in the ever-changing 
environment of HIV/AIDS is that of adherence to ART if access is garnered.  
Mannheimer et al. (2005) used a quantitative measure of quality of life among a study 
population beginning an ART regime.  They showed that 12 months into the regime 
subjects reporting 100% adherence to the ART had significantly higher quality of life 
scores than they did coming into the program or than subjects reporting lesser adherence.  
While Mannheimer et al. (2005) are using quantitative analysis, there is an implicit 
argument being made that adherence is an important component to both the physical and 
mental health of patients.  One of the contentions of my research is that the type of 
research Mannheimer et al. undertake should be followed up with qualitative research, 
adding context and depth to the data.  In addition to quality of life scores the level of 
adherence can affect the likelihood of transmission, with subjects with high adherence 
having lower viral loads, and the development of drug-resistance.  These issues are 
extremely important when dealing with marginalized populations where access may be 
sporadically available or structural limitations support “risky” behavior, such as sex 
without a condom, needle-sharing, or other illegal drug use.  Although the causal 
mechanisms between poverty and such “risky” behaviors are not clear there continues to 
be evidence which suggests that poverty, drug use, and “unsafe” sexual practices are 
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correlated.  Gorman et al. states that, “A number of studies suggest that among gay and 
bisexual men participation in unsafe sexual activities occurs in the context of drug use, 
which may have a dis-inhibiting effect” (Gorman et al. 1997: 508).  Furthermore, CDC 
statistics show that a large and increasing number of new HIV cases are among the urban 
and rural poor (Centers for Disease Control 2008).   
The theme of drug use, especially methamphetamine use (meth, crystal, etc) was 
common in both my interviews and participant observation.  One event I attended was the 
screening of a documentary about meth use in the gay community.  While not specifically 
relating to HIV/AIDS, it was telling that nearly 90% of those meth addicts included in the 
documentary were HIV positive.  However, the risks associated with meth use and other 
drug use, especially intravenous drug use, are quite different.  While meth can be boiled 
down into a liquid and injected it is most often kept in its solid form and smoked through 
a pipe.  As Gorman et al. points out meth use may trigger unsafe sexual practices, namely 
sex without a condom, while IVDU and needle sharing presents an inherent risk of 
injecting the HIV virus directly into one’s bloodstream.  Although there have been no 
studies, to my knowledge, which conclusively link poverty, drug use, and HIV risk, a 
recent government-funded study showed that meth users are three times more likely to 
test positive for HIV antibodies than non-meth users (amfAR 2005).  Furthermore, a 
critical reading of the available literature would suggest that these three issues are related 
through structural connections.  In fact, Smith asks, 
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Even when one can assume adequate knowledge, can one assume that people 
have the capacity to act on that knowledge?  For example, one may simply ask 
whether people have access to condoms.  However, a more sophisticated and 
theoretical manner of asking this question requires attention to issues of how 
sexual relations and condom use are negotiated within contexts of poverty, age 
and gender inequality, and other configurations of power that influence people’s 
priorities and constrain their choices (Smith 2003: 344). 
 
Thus, it is not the behavior of unsafe sex or drug use which may be understood as a 
structural constraint to HIV/AIDS prevention, but the power relationships and 
marginalization that shapes those decisions and behaviors which can be conceptualized as 
structural constraints.  When I write of these behaviors as structural limitations to HIV 
prevention and treatment, I mean not only the actual behaviors but also the power 
relationships that are at the root of these behaviors.      
 Bourgois, in his book In Search of Respect: Selling Crack in El Barrio, offers a 
pertinent example of the cyclical nature of poverty and drug dependence.  He posits that 
it is social marginalization which leads to poverty and, in turn, drug use, saying 
“substance abuse in the inner city is merely a symptom – and a vivid symbol – of deeper 
dynamics of social marginalization and alienation” (Bourgois 2003: 2).  This offers one 
of the most compelling cases in the literature for the relationship between poverty and 
drug use, the structural and behavioral.  While drug use and “unsafe” sexual practices 
may not be directly related to the structural factors of poverty, economic marginalization, 
lack of education, and language barriers, they are, no doubt, closely related to these issues 
in a recurring and substantial way.  Likewise, Bourgois’ work may be read as 
understanding poverty as a predisposition for substance abuse.  This is not to say that 
these two outcomes of economic marginalization are mutually exclusive, but that the 
positive correlations between the two are undeniable. 
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 Furthermore, Singer (1996), and many others, have related the connections 
between drug use and HIV infection.  It is Singer, however, who most notably addresses 
the syndemic nature of, what he calls SAVA (substance abuse, violence, and AIDS).  He 
contends that they are “not wholly separable phenomena,” (Singer 1996: 99) but that they 
are interdependent and fuel one another.  While Singer is addressing the issues faced by 
IVDU, generally, the extension to meth and other non-injecting drug users is clear, and in 
fact, in later articles (2003) he addresses the use of “mind-altering substances” (Singer 
and Clair 2003: 431) instead of injection drugs, specifically.  In one study he found that 
25% of IVDU he surveyed were infected with HIV and that poverty and homelessness 
was a significant predictor of disease burden and morbidity (Singer and Clair 2003).  
These data show the impossibility of separating the social and biological and the 
structural and personal components of illness risk and stresses the importance of 
biocultural and syndemic analysis. 
 Finally, Niehaus (1990) in her chapter in Culture and AIDS (Feldman 1990) takes 
an interesting look at the differences between people living with AIDS from the 
“professional” class and working class.  She contends that although the professional class 
generally has employer funded group health insurance which covers extended hospital 
stays, home healthcare, and expensive medications, those economic securities only mask 
the continued insecurity associated with the psychological and social costs of living with 
HIV/AIDS.  According to Niehaus, people without insurance or with poor quality 
insurance tend to rely on government and community-based support mechanisms, 
perhaps for obvious reasons.  The professional class, however, “relies primarily upon 
informal supports and on privately funded care” (Niehaus 1990: 189).  These informal 
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supports generally include family and friends and may be relied upon to ensure privacy to 
the individual and family from a stigmatizing illness among a social class where 
innuendo and association with “gayness” and HIV/AIDS may result in adverse social 
standing.  As Niehaus states, “Families will be there so long as their own ‘name’ is not 
compromised, and so long as the privacy of personal family affairs is respected by the 
PWA and his friends” (Niehaus 1990: 192).  This article relates well to my research 
where most of my informants did have private employer based insurance and many 
thought about the effects of disclosure on their families and friends as a function of 
maintaining informal support networks.    
My research is an attempt to add to the literature in several ways.  First, I think it 
extremely important to continue to stress the magnitude and severity of the HIV epidemic 
in the developed world, particularly the United States.  While much of the public health 
and anthropological attention has been shifted to the developing world, especially sub-
Saharan Africa, the rapid and far-reaching changes that are occurring in the United States 
are begging for the analysis of social science.  As Mannheimer et al. suggest as recently 
as 2005, “The relationship between QoL (quality of life) and adherence has not been well 
studied” (Mannheimer et al. 2005; 11).  And while amazing biomedical research 
associated with HIV/AIDS is taking place in the universities and research labs around 
this country, we are left to wonder what the effects of those medical breakthroughs are to 
the populations who utilize them most.  A more comprehensive understanding of ART 
and access to it on the social, psychological, and cultural milieu they serve should not be 
an afterthought, but a purpose of the field of medical anthropology.  Second, I believe the 
theoretical implications of my research are a novel and interesting approach to the study 
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of HIV infection.  While Foucault (1973) argues that only the physician has the 
authoritative knowledge to understand disease, and therefore a clinical gaze, I have 
suggested that the patient also has a certain authoritative knowledge which allows him to 
understand his illness in ways that make sense to him, and perhaps more sense than what 
a physician tells him, a reflexive gaze.  Thus, the patient creates a relationship with the 
illness which changes and undergoes revision constantly, but is always interpreted from 
the patient’s perspective.  This reflexive gaze certainly mediates and shapes the 
explanatory model and the ways that illness is relayed and talked about.  Third, I believe 
that the use of an explanatory model and illness narrative technique is the best way to 
elicit responses from subjects regarding illness.  While many studies have utilized these 
methods before, I hope to reiterate the efficacy and usefulness of such methods.  I, thusly, 
see my own research as contributing to the greater body of knowledge through applied, 
methodological, and theoretical avenues.  
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Chapter 5 
“I never talked about it:” Methodology: 
           
Methods Used: 
For this research project I conducted seven semi-structured interviews with self-
described people living with HIV/AIDS.  All of my participants were gay men between 
the ages of 22 and 45.  Generally, the socioeconomic status of my participants was 
between middle and upper-middle class, although one of my participants would be 
classified as lower-middle class.  Each interview lasted between 45 minutes and two 
hours with in-depth probing focusing on each participant’s interests and experiences.  All 
but one interview took place at a local coffee shop in Midtown Atlanta; the one exception 
was a phone interview.  Interviews were conducted between July 2007 and March 2008.  
I also attended three community educational forums sponsored by a local community 
based organization and free testing clinic between July 2007 and December 2007.  These 
forums focused on gay men’s health and HIV prevention and treatment options, 
specifically.  I spoke with two members of that organization, a full time staff member and 
a volunteer, informally at these events.   
In addition, I have conducted countless informal conversations over the past 
several years, both with people living with HIV/AIDS and other members of the Atlanta 
gay community, about how they conceptualize and understand HIV/AIDS, medically and 
socially.  This participant observation has certainly shaped and focused this research and 
my own understanding of HIV/AIDS in the American context.  I have been involved with 
a local community based non-profit organization which deals with prevention, testing, 
and treatment of HIV/AIDS for the last several years as a volunteer and fund-raiser.  
Again, although no data from this work is explicitly included in this thesis, my work with 
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this organization has helped me define and implement this research project and identify 
the research needs in this area.  Although I have worked with this organization for some 
time I was barred from any support group meetings and from directly approaching clients 
of the organization as interview participants because of concerns about the confidentiality 
of the participants. 
  I chose to conduct semi-structured interviews at set times and places with my 
participants.  This method adds a level of formality to the interviews, which I have 
consciously included because I do not know most of my participants personally and have 
little opportunity to interact, in a participant-observer context, with an “HIV-positive 
community.”  Because of these limitations I have recruited participants through mutual 
acquaintances using a snowball mechanism.  Therefore, I am using the formality of the 
interviews to develop a level of trust and rapport with my subjects.  I believe the 
interviews achieve this end by imparting a certain level of academic credibility and 
legitimacy to the participants.  In terms of the interview schedule (Appendix A), I created 
a set of 15 questions which I initially thought would get my participants talking about the 
issues of interest to this project.  Those questions went through a slight revision during 
the Institutional Review Board (IRB) process and were then put into practice.  I used my 
first several interviews as a pre-test stage (although the data collected is included in this 
final thesis), after which I revised the questions again.  I cut several questions which I 
came to think of as irrelevant, including questions about the eventual discovery of a cure 
for HIV/AIDS.  I also added questions about the daily tasks and obstacles associated with 
the complex antiretroviral (ARV) cocktail and the influence of that on adherence to ARV 
treatment.     
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Theoretical Basis of Research Design: 
My research methodology was designed to reconstruct issues surrounding living 
with HIV.  However, this very simple statement has many layers and caveats embedded 
within it.  To begin with, one research methodology is not appropriate for each situation 
encountered.  The experience of living with HIV is not static, but a dynamic and 
constantly changing process.  I have come to understand that the evolution of experience 
can be based on life events associated with being HIV positive, such as diagnosis, the 
introduction of treatment, and issues surrounding disclosure, as was initially expected.  
However, life events not directly associated with one’s HIV status can also have a 
profound effect on the way one deals with their serostatus.  Issues such as drug use, 
sexual activity, and family acceptance can directly impact not only how one creates an 
identity, or identities, surrounding HIV status, but also more tangible issues, such as 
treatment seeking behavior.   
To this day there continue to be debates within social science about the validity 
and analytic usefulness of the study of identity.  Brubaker and Cooper (2000) argue that 
“by stipulating that identities are constructed, fluid, and multiple – leaves us without a 
rationale for talking about ‘identities’ at all…” (Brubaker and Cooper 2001: 1).  
However, much of the work done on HIV-related identity construction has tended to 
conceptualize identity as a “thing;” for example, racial identity, sexual identity, or gender 
identity.  The questions being asked are how does HIV interact with these previously 
constituted and traditionally recognized normative social/biological identities.  The issues 
of identity creation based specifically on serostatus have received negligible attention in 
the literature.  This is a conceptual, theoretical, and methodological point.        
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Methodologically, how one approaches the study of identity must be altered to not 
impose or constrict the natural fluidity and plasticity of identity creation and, what I have 
called maintenance, referring to the constant revision and updating of how one defines 
himself.  In order to do this I have employed a hybrid technique of Arthur Kleinman’s 
idea of focusing on the explanatory model (1988).  Kleinman espouses a methodology 
which allows for the definitions of sickness, illness, and suffering to come directly from 
the patient to the health care professional.  This allows the patient to define their own 
relationship with their illness.  This was, and is, a novel approach to how illness is 
conceptualized and treated, in a biomedical sense.  While Kleinman did not deal 
specifically with how those explanatory models were interpreted to signify identity, he 
did elucidate how and why they could assist in the diagnosis and interpretation of the 
health care professional.  Therefore, I have modified the explanatory model paradigm to 
be more useful in assessing the more intangible concept of identity.   
Kleinman’s concept of allowing the explanation of illness to come directly from 
the patient who embodies that illness is an important cornerstone in assessing identity 
also.  This methodology allows for a more organic and holistic interpretation without 
imposing a researcher’s preconceived notions onto the patient.  Through the use of 
explanatory models coming directly from the participant, the participant can then 
enunciate what and how they are feeling about their illness.  This information will then 
have to be interpreted by the researcher, which may or may not represent the emic 
perspective.  However, I believe the most organic way of defining identity is allowing it 
to come directly from the participant.  However, when attempting to assess past feelings 
and perceptions of illness, the participant’s memory of those emotions is subject to 
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revision.  While this revisionary technique is a perfectly valid form of identity analysis, 
the actual nature of events, feelings, and perceptions can never truly be determined.  
Because of this limitation, using the current state of the patient, and their revised 
memories, to assess their past and future illness trajectories is an important process.   
  All of these issues, revisions, and additions are an attempt to collect more 
coherent and accurate illness narratives.  Illness narratives, as enunciated by Arthur 
Kleinman, are an attempt to reconstruct memories, events, or feelings to “give coherence 
to the distinctive events and long-term course of suffering” (Kleinman 1988; 49).  Much 
like Foucault (1973), Kleinman focuses on the physical, psychological, or, in many ways, 
tangible aspects of disease and suffering.  However, Kleinman’s paradigm takes into 
account the cultural significance of disease to the patient, as well.  When speaking of a 
homosexual patient suffering from chronic pain in the late 1980’s, Kleinman says, “AIDS 
holds powerful cultural meanings in Western society, and its social construction as the 
latest and most deadly venereal scourge, as a modern plague, is something we have all 
read about in the newspapers and magazines and seen on television” (Kleinman 1988; 
84).  From a clinical perspective these insights may be irrelevant, but increasingly, the 
biomedical community is realizing the importance of social, cultural, and even personal 
beliefs of illness on the health outcome for patients.  Thus, a study designed to collect and 
interpret these beliefs has the potential to inform the medical and public health 
communities and influence the ways in which people living with HIV/AIDS are 
consulted about their serostatus and the associated logistics and treatments.   
However, many previous studies have documented illness narratives from people 
living with HIV/AIDS (Bloom 2001; Gorman et al; 1997; Siegel and Krauss 1991; 
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Whittaker 1992).  All of these studies conceptualize HIV infection from particular 
agendas, as would be expected.  Different “at-risk” populations are singled out and 
macro-level theories are applied to the analysis of the illness narratives.  Of course, my 
particular study is the same, looking at specific sub-groups and utilizing particular bodies 
of theory.  The successful use of illness narrative and explanatory model approaches in 
these and other studies legitimizes the continued use of such models in further research 
on living with HIV/AIDS.  My research can then continue to support such methods for 
the study of chronic and infectious disease.  That is not to say that these methods do not 
have disadvantages.  As I have already pointed out, the recollection bias associated with 
the reconstruction of past feelings and events necessarily distinguishes what people 
remember from what “actually” happened.  However, what people remember is also an 
important component to assessing and interpreting how people have reconstructed their 
current frame of mind, or identities.  It is, in fact, remembered experience which 
continues to inform how people act and react to current situations, both situationally and 
relationally (Evans-Pritchard 1940; Kondo 1990) - situationally, in the sense that people 
react to different situations and identify themselves in opposition to other, what are 
conceptualized as outside, people or groups (Evans-Pritchard 1940) and relationally, in 
the sense that concepts of identity vary depending on whom a person is interacting with 
(Kondo 1990). 
 An added layer in my study to the collection of illness narratives is the component 
of if/how access to treatment alters the ways in which identities formed around illness 
would otherwise be created and maintained.  This point can be both intertwined and 
separated in the collection of illness narratives.  In my interview schedule I have included 
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several questions that ask about treatment specifically and whether that treatment altered 
the subject’s outlook on their illness.  Important to this line of questioning is also the 
added dimension of adherence to treatment; why adherence is maintained or 
discontinued; what is the level of compliance with a health care professional’s 
recommendations; and whether exclusive or complementary alternative therapies are 
used.  Beginning and stopping treatment for HIV can produce many complications and 
outcomes.  From a biomedical standpoint, sporadic adherence can lead to the 
development of drug-resistant strains of the HIV virus, which can then be passed on to 
other individuals (Blankson 2005).  It can also complicate future treatment if the virus no 
longer responds to previously prescribed medications.  However, from a social and 
personal perspective, sporadic adherence can seem like the best option for the person 
living with HIV/AIDS.  A subject may discontinue treatment if symptoms go away, their 
T-cell count returns to “acceptable” levels (500 cells/mm2) (amfAR 2006), or they no 
longer feel like treatment is helping or necessary.  I would call these more personal 
factors which have received a great deal of attention in the literature (Bloom 2001; 
Gorman et al. 1997; Smith 2003), but in my own research I have identified several 
structural factors which also can affect optimum adherence to treatment.  These factors 
include both the financial aspects and, more likely, time constraints associated with 
filling prescriptions and scheduling doctor’s appointments, illegal drug use which affects 
priority decision-making, and the stigma of treatment seeking behavior, which often 
necessitates serostatus disclosure to family, employers, and insurance companies. 
These structural constraints to both treatment and adherence have methodological 
repercussions in terms of research and interview design.  The research design must be 
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able to focus on the structural mechanisms at work.  This is why, in addition to interviews 
with people living with HIV/AIDS, I have also included a participant-observation 
component, attending community-based discussion groups targeted at HIV awareness, 
mostly in the gay community.  These discussion groups can offer a more concrete 
explanation of the actual process and options for acquiring ARV treatment in the area.  
Some of these organizations actually have funding to provide the treatment themselves.  
The issues associated with HIV testing are similarly important.  The differences between 
anonymous and confidential testing and the repercussions for insurance coverage can 
have profound effects on newly diagnosed people, where any positive test result from a 
confidential test is legally required to be forwarded to state and federal departments of 
health and the diagnosis being noted as a pre-existing condition when applying for 
insurance coverage, whereas an anonymous test result cannot be shared with any outside 
agencies.  In terms of interview design, a more concrete and tangible structure needs to 
be employed.  In the literature, illness narratives often focus solely on perceptions and 
feeling about illness, but not on how the climate within which one lives effects those 
perceptions and feelings.  Understanding that treatment seeking and adherence behaviors 
are influenced by both personal and structural forces can better inform a more holistic 
and complex view of the nature of living with HIV. 
 There are, of course, a myriad of ethical issues which surround and encompass 
research on both personal and structural issues associated with living with HIV/AIDS.  
The collection of illness narratives from people living with HIV/AIDS can be a difficult 
process for the participant and the researcher.  Creating a frank, yet sensitive interview 
schedule is a large component of conducting ethically sound research, especially when 
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discussing the trajectory of a “chronic” yet eventually fatal disease, such as AIDS.  Great 
care was taken on my part to word questions in ways that are hopeful and continuous.  
However I found that most of my interview participants were very open to talking about 
their serostatus and well-adjusted, in terms of coping with and understanding the 
biomedical, social, and personal ramifications of living with HIV.   It made it easier that 
my study was designed to look at the past and present, and future plans or expectations 
are only marginally discussed.  Of course, many subjects want to talk about how they 
expect to be or act in the future and those conversations do find their way into the 
interviews; however those feelings are not the main focus of my research.   
I have also collected a list of local HIV/AIDS counseling and support groups for 
dissemination to participants, should they have requested or appeared to need them.  
However, I have found that most of my participants have an extensive knowledge of what 
local resources are available to them, even to a greater extent than I do.  Another 
important aspect to ethically sound research is the benefit of the community to which one 
is researching.  In the long-term this study lays the groundwork for a longer more in-
depth study which should have concrete beneficial application.  The methodologies 
employed in this study are, thus, designed to maximize theoretical and applied outcomes, 
as well as add relevant and novel information to the appropriate literature. 
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Chapter 6 
“More difficult than having a crack baby:” Living with HIV. 
 
Results: 
 
As I was initially conceiving of and developing my research questions and 
methodology, I conceptualized “identity” as an important component to how people live 
with and manage HIV/AIDS.  Furthermore, I hypothesized that “access” to ART had 
something to do with how those identities were developed and maintained.  While my 
research has supported this initial conception, to some extent, what I have realized is that 
whether a person has access at all and how they access ART has far more consequences 
than the development of an HIV-related identity.  Whether and how people access ART 
has consequences for the development of drug resistant HIV, “opportunistic” infections, 
transmission schemas, disclosure possibilities, and social and economic marginalization.  
These issues struck me as, somehow, more pertinent than an ephemeral notion of “HIV 
identity.”  Likewise it was these issues that my informants wanted to talk about.  As the 
following pages will illustrate, my informants cited structural impediments to ART 
access as major barriers to adherence.  It is these external agents which predominately 
shape the access landscape, at least for my participants.   
Structural and agentive factors contribute to how people living with HIV/AIDS 
create and renegotiate identities based on their condition.  By condition, I mean both their 
illness, as well as their economic, personal, psychological, social, and historical 
viewpoint.  While each of my informants cited different factors and emphasized different 
sources of influence in how they conceived of their condition, there are definite themes 
which have emerged that link the individual experiences of my informants.  Some of 
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those themes include the perceived connection between sexual orientation and HIV 
infection, the trust placed in biomedical treatment, the influence of structural factors on 
the availability of testing and treatment options, and lack of disclosure to the immediate 
family.  Obviously, these themes are not ubiquitous, but each informant echoed at least 
two of these themes, to varying degrees.  I will offer three case studies to illustrate these 
themes. 
Gary: 
 Gary is a 30 year old pharmacy manager who was diagnosed with HIV in 2002 at 
the age of 24.  However, he and his physician have estimated that he was initially 
infected one year previous to the diagnosis after he suffered a year with reoccurring and 
misdiagnosed tonsillitis, leading to three separate hospital stays.  After his diagnosis his 
long-term tonsillitis was attributed to immuno-suppression, caused by his low CD4 cell 
count and HIV infection.  He is currently on an ART combination which is part of a 
clinical trial by a large pharmaceutical company testing a new class of ART which is 
designed to inhibit the integration and bonding of the HIV virus to the white blood cells it 
attacks.  He initially became involved in the trial because his primary care physician is 
also the primary investigator for the trial and for the AIDS Research Consortium of 
Atlanta (ARCA).  As a pharmacy manager, Gary had insight, not only to his own 
condition, but also to the larger pharmaceutical industry and the patients he serves.   
 Gary articulated all of the prominent themes I have identified.  During our 
interview he told me that it “made sense” to him that he would eventually contract HIV 
because he is gay.  He explained that growing up in rural Appalachia, what he saw about 
HIV was “mediated through T.V.” and linked being gay with certain HIV infection.  It is 
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because of this upbringing that he has not disclosed his sexual orientation, nor his HIV 
status to his immediate family.  As he contends, if he is “not dying, they don’t need to 
know.”  He noted that his compliance to ART is good and that he “never took a vacation 
from meds,” but that he “can see non-compliance” in the patients he serves.  When I 
asked Gary if he had ever experienced HIV-related stigma he responded by pointing out 
that he has never faced discrimination in the workplace and most of the stigma he felt 
was in dating.  He said that he tends to “serosort,” or seek out other HIV-positive 
partners, and he outlined a paradigm based on age for how people respond to his status 
disclosure.  He mentioned that older men tend to understand and empathize with him 
because they lived through the beginning of the AIDS epidemic and experienced 
extremely high rates of infection among their friends and community.  Men in the middle 
of the age spectrum Gary characterized as scared of and avoiding people living with 
HIV/AIDS, at least sexually.  These were members of a generation conditioned into fear 
of HIV by the previous generation and also the first to effectively prevent infection 
because of expanding knowledge about transmission.  And finally Gary characterized the 
youngest tier as naïve and reckless; those who were not born yet or are too young to 
remember the early epidemic and have grown up in an age where AIDS did not mean a 
quick and certain death for most.   
 Gary pointed to his work as a pharmacy manager in shaping how he thought and 
felt about HIV, in general.  He clearly understood what impediments people living with 
HIV/AIDS faced when dealing with the healthcare sector; physicians, insurance 
companies, and pharmaceutical companies.  He suggested the increase in generic 
pharmaceuticals, whose availability is rapidly growing, is one of the most important and 
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meaningful changes to positively effect people living with HIV/AIDS.  However, many 
of the people he sees in his pharmacy are wary of generic drugs and, to some extent, 
unwilling to switch over to them.  Furthermore, rising prescription co-pays often stretch 
thin the financial capacities of ARV consumers.  These structural limitations were central 
to how Gary conceptualized living with HIV and he saw his work as a pharmacy manager 
as an opportunity to alleviate some of those limitations by ensuring proper drugs were in 
stock, catching mistakes in physician prescriptions, and working with his customers to 
understand their insurance policy or the opportunities for government assistance.  From a 
more personal perspective, Gary characterized living with HIV as “more difficult than 
having a crack baby.”  From his standpoint, HIV is an entity, separate from himself, 
which exists inside him and, to some extent, functions independently from him.  It is a 
condition that requires constant attention and affects all facets of his life, regardless of the 
efficacy of ART.  Although ART can limit the physical manifestations of HIV, its specter 
is ever-present in Gary’s social and medical life.  He trusts his doctor to make beneficial 
decisions about his health for him and believes in the ability of biomedicine to maintain 
control over his “crack baby.” 
Gary personified all four prevalent themes I identified and my interview with him 
largely convinced me that the structural factors affecting access to ART continue to be of 
great concern to people living with HIV/AIDS, even in the United States.  While these 
structural constraints are mediated by existing power relationships and often 
disproportionately affect the socially and economically marginalized, including gay men, 
there is also a certain level of personal control, or agency, which may or may not be 
mediated by and mediate these constraints.  Gary would characterize his experiences with 
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HIV as relatively “lucky,” as would most of my informants.  He has been afforded a level 
of personal agency which allows him to choose to utilize condoms, select his sexual 
partners, receive ART and use it adherently.  He can schedule doctor’s visits, continue to 
work, which provides him with high-quality private insurance coverage, and participate 
in medical trials.  His level of cultural capital and personal agency disassociate him from 
many of the structural constraints he identified and which he sees in his pharmacy 
customers.  However, not all of my informants shared this relatively elite status. 
Tyrone: 
 Tyrone is 22 and has been living with HIV since 2006.  He was diagnosed when 
he was 20 years old after an extended hospital stay for a bacterial infection.  He is a 
college student and does not have private insurance, but has been utilizing ART for 
almost two years through ADAP and state funded healthcare for people with low-
incomes.  His current ART regimen consists of one combination pill a day, which 
includes three different ARV’s.   
 Tyrone also articulated all four of the prominent themes.  He characterized his 
condition as an “emotional burden,” not only for himself but for the people to whom he 
disclosed his status.  This is one reason why he has not told his immediate family of his 
status and has had a difficult time telling his closest friends, whose reactions tended to be 
more emotional than his own.  He was also concerned about the reaction of his family, 
both to his serostatus and also to his sexual orientation.  He characterized his family as 
“one of those kinds of families” who would think “HIV isn’t a gay thing, but if you were 
straight this wouldn’t have happened” and conceptualized disclosing his status to his 
family as “a second coming out.”  Much like Gary, Tyrone had internalized a correlation 
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between being gay and becoming infected with HIV.  After his initial diagnosis Tyrone 
described a period where he attempted to “re-normalize” and undo the damage that the 
diagnosis and extended hospital stay had caused in his life, both emotionally and 
logistically.  As a result of the length of the hospital stay Tyrone lost his house, his 
family, his friends, and his health because he was unable to work while in the hospital 
and unwilling to disclose his status to friends and family which caused a decrease in the 
level of intimacy and trust with those closest to him.  After his diagnosis he attempted an 
“adjustment to a more stable life.”  Tyrone found comfort in a traditionally black church, 
where he eventually entered into the leadership, and said about his status that “it 
enhanced it [his faith].”  He has disclosed his status and sexual orientation to the 
leadership of his church, which, he says, has a large HIV-positive congregation.    
 However, Tyrone also saw structural issues as central to how people think about 
and perceive HIV/AIDS today.  He acknowledged that his own circumstance, receiving 
ART through government assistance, had led to his inconsistent adherence.  He also saw 
a lack of proper and relevant education as a key impediment to the fight against 
HIV/AIDS, specifically through the work that his church engages in, which involves 
regular support of local HIV-related prevention and treatment organizations and plans to 
institute its own free testing clinic.  In his own experiences he has seen little to dissuade 
common misconceptions about HIV/AIDS, saying “most people have a 1987 view of 
AIDS and this is 2008.”  He also gave an example of this when speaking about how 
people need to put “information in context” and understand that while a low viral load 
count may reduce the chances of passing HIV to a partner, an undetectable viral load 
does not mean that you cannot transmit the virus, as he contends many people believe.   
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 In Tyrone’s case, HIV was certainly mediated and understood through his views 
and beliefs about being gay, but also by the lifestyle that he sees going along with that 
identity.  His discussion of the need to “re-normalize” and an “adjustment to a more 
stable life” were clearly within the context of being young, gay, and participating in the 
activities that he understood that to entail, namely binge drinking and being sexually 
promiscuous, relative categories he did not define in our interview.  From a personal 
agency standpoint he did, and does, have the ability to make decisions regarding whom 
he engages in sex with and whether or not to use a condom.  However, after his 
diagnosis, his ability to access the appropriate healthcare in a timely manner, on his 
terms, has been severely curtailed because of his lack of insurance and reliance on 
government funded programs.  He does not have the ability to alter the regimen he is on 
and his options, if that regimen were to become ineffective, are significantly reduced 
compared to someone with private insurance.  His level of agency within the healthcare 
sector is, thus, greatly reduced.  Tyrone’s reflexive relationship with HIV was 
characterized by the “emotional burden” it placed, not only on him, but the perceived 
burden on his friends and family to whom he disclosed his status.  The issue of disclosure 
was central to him and the responses and reactions of those close to him were of utmost 
importance to him when making decisions about who to disclose his status to, and when.  
Tyrone felt that his power and agency came from being able to disclose or not disclose 
his status to whom he chose when he chose to do so.  
Jake: 
 Jake is a 37 year old man who has been living with HIV for approximately 15 
years.  He thinks he contracted HIV while engaging in unsafe sex while under the 
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influence of methamphetamines.  In fact, Jake is a recovering meth addict, a common 
correlate with HIV infection, especially among gay men.  He has never taken ART, with 
the exception of a one week trial in 1996 when, he says “they were putting everyone on 
the new drugs.”  Jake has consistently sought alternative treatments and is currently 
utilizing herbal teas, meditation, and yoga as his treatment schema.  When asked if he 
would ever consider using ART if his health worsened or his CD4 cell count began to 
decline he emphatically replied that he would, but that that situation had not yet presented 
itself.  The personal agency needed to make such a decision implies the ability to research 
and access alternative therapies, independent of a healthcare provider’s 
recommendations, and also work outside of the dominant insurance paradigm which 
shapes much of the healthcare access landscape in the United States today.   
 Jake’s experiences offer an interesting example of the hard to define, yet ever 
present link between meth use and increased risk for HIV infection.  As discussed 
previously, meth itself generally does not present an inherent risk, but the effects of meth, 
which is known to reduce inhibitions and increase sexual pleasure, often cause an 
inability to make decisions and increase the desire for sex.  Furthermore, meth is 
extremely addictive, often after only one or a few uses.  Jake expounded upon these 
phenomena in our interview, and he felt lucky, in many ways, that HIV was the only 
consequence of his years of drug use.  Jake fell into meth use to cope with a bad family 
situation and his eventual final resort, which was to run away as a teenager.  Again, the 
epidemic of homeless gay youth, fleeing abusive or un-accepting family situations is, 
most certainly, partially responsible for the growing rate of incidence of HIV among 
young gay men in recent years.   
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 From a personal perspective, Jake understood his diagnosis and subsequent events 
as a “wake up call” to, again, stabilize his life and exit the lifestyle he associated with 
young gay men, namely binge drinking, drug use, and promiscuous sex.  While Jake 
never entered the dominant healthcare paradigm after diagnosis, he conceptualized his 
HIV infection as a spiritual awakening to take care of his body, which, for him, involved 
exploring alternative therapies.  This divergence from the dominant paradigm suggests, in 
Jake’s case, high levels of personal agency and the ability to seek out and pay for 
alternative therapies not covered by insurance plans.  Jake’s story embodies the fewest of 
the prominent themes I have outlined, as he has disclosed his status to his family and 
does not utilize ART, even though he does not necessarily distrust biomedicine.  He was, 
however, unable to escape the power structures which mediated his meth use and also 
had internalized the hegemonic constructions of HIV/AIDS as ubiquitous among gay 
men.  Jake’s case is best characterized as one of hope, leading to the recovery of a meth 
addict and finding an emotional and personal center in health and life.   
I have selected these individual case studies, because they, in many ways, clearly 
illustrate the broader themes I have found in my research.  In addition to these three 
cases, I conducted four other interviews with gay men living with HIV in the Atlanta 
area.  Curtis, who is approximately 50 years old, was diagnosed in 1982 and began taking 
AZT in 1989 and ART in 1996.  He currently takes two ARVs and an additional 12 
medications a day.  These additional medications are all related to the side effects of 
ART, although he is the only one of my informants to report such high morbidity 
associated with pharmaceutical side effects.  He characterized ART as “long-term 
chemotherapy” as he made associations between the treatment of HIV/AIDS and cancer.   
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Curtis is also involved in AIDS activism within the faith-based and activist 
communities.  He serves on the board of a local HIV/AIDS treatment and testing center 
and is the national AIDS liaison for the Episcopal Church.  Curtis trusts the efficacy of 
biomedicine and his doctor’s recommendations to treat HIV and noted that he has a 
degree in biology when he explained that he conceptualized HIV/AIDS from a clinical 
and biomedical perspective.  He was my only informant who attributed his serostatus to 
behaviors, not identity, saying it is contracted through an “activity, not who you were.”  
This is perhaps because he was diagnosed before much was known about the 
transmission of HIV and, therefore, cannot be held “accountable” for his status.  My 
other informants were all diagnosed after transmission routes were firmly established 
and, perhaps, blame gay identity with infection as an attempt to justify their involvement 
in known “risky” activities; activities that they understand as a part of being gay. 
 Mark is a 33 year old gay man who was diagnosed with HIV in 1994.  Along with 
Curtis he was the only one of my informants to be tested regularly before his diagnosis.  
He also attributed his serostatus with gay identity, saying that he expected it and, 
therefore, “never really freaked out…about it.”  After researching internalists who 
specialized in HIV medicine he went through a short period of trial and error with 
medications before settling on his current combination of 3 ARVs.  He did not begin 
treatment until 2000 at his doctor’s recommendation.  He has not disclosed his status to 
his immediate family except for his sister saying that his “mom had a tough life,” and it 
was not necessary to do so.  Once again, Mark exemplifies the themes of trust in 
biomedicine, not questioning the authoritative knowledge of the healthcare professional, 
and being influenced by the public health hegemony which associates being gay with 
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eventual HIV infection.  An interesting caveat to the theme of placing trust in the 
healthcare professional is that five of my seven informants did not research treatment 
options and are currently taking a doctor’s recommended regimen.  However, they all 
spent considerable time researching doctors.  The personal agency being activated is at a 
different level than I had anticipated.  These informants have the ability to choose a 
doctor within the, often, broad scope of their insurance coverage and HMO plan.  While 
they do not activate their agency to work outside of the healthcare system or research 
ART independently of their doctor, they have already done enough, in their minds, to 
ensure their continued health by placing themselves in the care of a doctor they have 
hand selected and, in many cases, spent considerable time finding.  Tyrone was my only 
informant who was barred from this process because of the structural impediment of lack 
of insurance coverage.  He has no options in his treatment schema which is prescribed to 
him through a state funded health program. 
 Brian is approximately 45 years old and was diagnosed with HIV in 1995.  He 
thinks he contracted HIV while engaging in oral sex with an anonymous partner.  
Although he cites this “risky” behavior as the reason why he contracted HIV he still 
anticipated such a diagnosis because of his sexuality, saying “living through the early 
epidemic everyone who got it was gay and we didn’t know why, I was surprised it took 
me so long.”  Although the transmission routes became more clear by the time Brian was 
diagnosed, he was unaware of the risks associated with oral sex.  Again, Brian’s 
conception of risk was mediated through behaviors he associates with being gay, but 
these behaviors are merely a side effect of a lifestyle shaped by hegemonic constructions 
of what it means to be gay in the United States.  These constructions are largely meant to 
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“exoticize” the gay population and have had the effect of keeping relevant prevention 
education cloistered because many of the behaviors associated with gay men are deemed 
taboo by the public imagination; behaviors such as anal intercourse and oral sex.  A 
discourse surrounding such behaviors, especially oral sex, is only recently being 
developed in prevention programs and is largely limited to self-selected participants, in 
my experience.  These behaviors have, thus, becoming inseparable from gay identity and 
attribution of risk is tied to both, behavior and identity.  When I say that my informants 
“blamed” their sexual orientation for their HIV infection, it is impossible to separate that 
from the behaviors which that identity entails.  However, it is important to note that those 
are often stereotypic behaviors that have been ingrained into the public imagination 
through hegemonic discourse and may or may not be attributable to actual causation of 
infection.  It is, therefore, the identity construction, not individual behaviors, that many of 
my informants understand as being responsible for their infection, which is not 
necessarily related to particular behaviors. 
 Jay is 25 years old and was diagnosed with HIV in 2005.  He is currently utilizing 
ART through employer provided insurance.  He is concerned, however, that his insurance 
may soon be revoked because he is a part-time employee and apprehensive about the 
state of the economy and the company’s willingness to continue offering insurance 
coverage to part-time employees.  He was only marginally aware of state provided 
assistance programs for accessing ART and skeptical of their efficacy and availability 
and seemed unwilling to look into such a possibility further.  Jay has clearly 
conceptualized his condition as a chronic illness and said, it “hasn’t impacted me hardly 
at all.”  He lauded the “wonders of the drugs” and said he only felt “very minor” stigma 
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attached to being HIV-positive.                
In addition to the formal interviews there are several important findings which 
emanated from the participant-observation component of my research.  Patrick, the full 
time employee of the community-based organization, suggested that the gay population 
in Atlanta has an overwhelmingly accurate biomedical model of HIV transmission, but 
that there were still high levels of confusion about certain “higher risk” behaviors that are 
not common in the discourse of HIV prevention.  Most people know that unprotected 
anal intercourse and the introduction of bodily fluids, such as semen, to abrasions is 
deemed extremely high risk, most people do not know what risk is associated with 
unprotected oral sex or other behaviors not frequently discussed because of possible 
taboos on such behavior.  What Patrick was trying to demonstrate to me was that most 
people know the extremes of risk, basically what is and is not “risky.”  However, the 
level of knowledge begins to decrease when behaviors which fall in the center of the risk 
continuum are assessed by individuals.  In the rationalization and justification stage of 
deciding whether or not to engage in a behavior people draw on past experiences and 
knowledge to inform their decisions.  When people have never been told that brushing 
your teeth before engaging in oral sex can increase your likelihood of contracting HIV 
(an example of prevention information which was relayed to me during an educational 
forum), for example, they have no frame of reference with which to evaluate those 
behaviors.  Addressing these issues and reducing the stigma attached to “taboo” 
behaviors in order to tackle them with a broad audience are key components to 
developing more accurate and useful educational prevention programs.  This is one 
example of how the prevailing prevention education contributes, or does not contribute, 
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to understandings of HIV transmission for the general public.  These educational forums 
often consist entirely of self-selected participants who seek out the educational 
opportunity, and are not known or available to those at highest risk.  This same level of 
information is, generally, not accessible to the lay population and illustrates, once again, 
that proper education is lacking in the majority of HIV-related discourses.             
I have characterized my findings as a confluence of personal agency and 
structural impediments to healthcare access.  However, the specter of stigma and 
discrimination cannot remain absent from any discussion of HIV/AIDS and because of 
that I had considerable difficulty in recruiting research participants.  I contacted, through 
personal acquaintances, over 20 possible research participants, as well as contacting five 
HIV/AIDS-related support agencies.  Of those contacted, only seven were willing to 
participate in this research and none of the agencies were supportive of assisting my 
research.  Using my recruitment contacts as sources of information, because I did not 
actually speak to many of the people who refused to be interviewed, many of those who 
refused did so because they were either still dealing with the emotional upheaval of being 
newly diagnosed and had not disclosed their status to many people or they did not think 
they possessed adequate knowledge to participate in an interview about HIV.  Both of 
these findings are interesting and support the claim that there continues to be 
considerable stigma and discrimination pertaining to HIV/AIDS. 
 Many of my recruitment contacts conveyed responses from possible informants 
who refused to participate about their unease talking about living with HIV/AIDS.  Most 
of these people were newly diagnosed and had not disclosed their status to many people.  
Even after I had assured my recruitment contacts that all information was confidential 
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and academically sanctioned, their trepidations were not alleviated.  While this 
discomfort with speaking about their condition could be caused by a multitude of factors, 
and vary between individuals, there is no doubt that personal feelings of judgment and 
stigma are factors in making these decisions.  It is clear that personal feelings of stigma 
influence who people living with HIV/AIDS are willing to openly talk to about their 
condition.  It may be for this reason that my informants did not describe feeling high 
levels of stigma but, it would seem, many of those who chose not to talk with me did.  
This may be a result of a selection bias.   
Furthermore, according to my recruitment contacts, many people who refused 
participation did so because they did not feel they had adequate knowledge of HIV/AIDS, 
from a biological and pharmaceutical perspective, to complete an interview regarding the 
subject.  Again, I attempted to clarify my position by indicating that no formal knowledge 
of HIV/AIDS, its treatment, or transmission was necessary to participate in the study.  
Even after such a clarification, none of the prospective informants reevaluated their 
refusal to participate.  Clearly, these possible participants anticipated what information I 
was seeking and withdrew themselves from considering involvement if they did not feel 
they possessed such information.  This phenomenon also represents a methodological 
bias, with the informants responding to the investigator in the ways they expect or 
assume are appropriate or correct, or in this case not participating in the research at all.  
However, there may be additional underlying assessments by the prospective informants 
of judgment from the investigator.  They may assume a negative judgment from the 
investigator because they do not possess high levels of knowledge about their condition 
and are attempting to avoid such a judgment.   
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 This assessment can lead us to two intertwined conclusions.  First, the prospective 
informants who refuse to participate because they lack adequate knowledge of their 
condition are anticipating negative judgment and have been habituated to the expectation 
of stigma based on their illness.  This expectation of judgment and stigma indicates that a 
pervasive stigma still exists regarding HIV/AIDS and those living with the illness are 
careful to avoid such stigma.  Secondly, a reflexive gaze paradigm may offer interesting 
explanations to why these people do not feel they possess adequate knowledge about 
their illness.  This paradigm would suggest that understandings of one’s illness are 
constantly updated and, especially in post-industrial Western society, biomedical and 
pharmaceutical knowledge is a key component to those understandings. 
Analysis: 
Access to ART is only one aspect in the larger picture of living with HIV/AIDS.  
There is always present a personal relationship with the illness that shapes how people 
living with HIV/AIDS act and react to people, information, and the “outside” world.  
This reflexive gaze conveys meaning, bi-directionally, between the person and his or her 
illness.  This is to say that the illness informs the person and the person informs the 
illness, through adherent use of ART and through the effects of a strong and ever present 
mind/body connection.  A person’s actions and feeling regarding their illness can have 
profound effects on the quality of life and outcome of that illness.  Thus, the mental 
health of a patient has implications for the biomedical trajectory of the illness.  It is for 
this reason that understanding how a person living with HIV/AIDS experiences and deals 
with their illness, from a personal and social perspective, is an important component to 
better treating HIV/AIDS from a holistic and patient-centered perspective.  This is not to 
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say that personal agency and structural limitations should be viewed as dichotomous, but 
complementary, intersecting and fueling each other.  First, I will outline the structural 
limitations to ART access my participants have articulated.  I will then contextualize 
those data within a larger socio-political and economic landscape.  Secondly, I will 
analyze how personal decisions to utilize ART effect the creation and maintenance of an 
HIV-related identity by using the personal illness narratives of my participants.   
Of my informants, most of whom were currently utilizing ART did so through 
private insurance.  One of my informants garnered access through ADAP and a state 
provided health care program, which was free of charge to him.  However, the structural 
limitations associated with utilizing government funded health care were numerous and 
after his diagnosis he was unable to receive a follow-up doctor’s visit for four months.  
He commented on the confusing and burdensome bureaucratic “red tape” which 
contributed to his sporadic adherence to ART, even though his “cocktail” was the easiest 
to maintain, with only one combination pill a day.  The rest of my informants reported 
optimal or near optimal adherence with more intricate and encumbering ART regimens, 
with one of my informants, Curtis, taking a total of 14 medications a day, two ARVs and 
12 meds related to the side effects associated with those ARVs.  All of those informants 
received ARVs through private insurance.   
 It is clear that adherence is a critical issue to the proper and optimal treatment of 
HIV and how one gains access to treatment can have profound effects on its adherent use.  
Less than optimal adherence has the potential to increase the likelihood of developing 
drug-resistant HIV, which can not only be transmitted to others, but also complicate 
future treatment options.  However, the relatively fast rate of development of new drugs 
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and new classes of drugs helps curb this issue, especially in the United States where most 
drugs are available to the average consumer.  In fact, Gary, age 30, characterized his 
experience with starting an ART regimen as trial and error, with different drug options 
and combinations being tested, under his physician’s supervision, to determine their 
efficacy, at the individual level.  While this luxury is not shared throughout most of the 
world, especially in many developing countries, the decisions to begin and maintain ARV 
treatment are multitudinous and often confusing.  Five of my informants began ART 
immediately or soon after being diagnosed based on the recommendations of their 
physicians.  Curtis began taking AZT in 1989 and has had no interruption in his treatment 
since then.  However, the CDC and WHO generally recommend not beginning an ART 
regimen until CD4 cell counts fall below 500 cells/mm2 (amFAR 2005).   
This contradiction is, at least, partially explained by the time of diagnosis.  Five of 
my seven informants, Gary and Tyrone included, were not routinely tested for HIV and 
received their diagnoses due to the onset of opportunistic infections which led to 
extended hospital stays in both cases.  In Gary’s case he was diagnosed with tonsillitis 
and hospitalized three times over the course of a year before he was eventually diagnosed 
with HIV and his ongoing illness attributed to immuno-suppression.  When he was 
diagnosed in January 2002 his T-cell count was 176 cells/mm2.  Likewise, Tyrone was 
hospitalized in August 2006 because of the onset of a bacterial infection.  He explained 
that after being initially treated for the infection, the ER doctor explained that they were 
going to test him for HIV because of the severity of the infection and the possibility of 
immuno-suppression.  It was not until several days later that he received the results, 
during which time he had “prepared” for the possibility of a positive diagnosis.  At this 
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time his T-cell count was around 300 cells/mm2.  Four months later when he had his first 
follow-up visit and ARV’s were prescribed his T-cell count had fallen to around 180 
cells/mm2.   
An important and interesting question to be considered is why neither of these 
people, both of whom saw a correlation between being gay and HIV infection, got tested 
regularly.  Both were diagnosed in the early to mid 2000’s and lived in Atlanta at the time 
of diagnosis.  Free testing centers were numerous at that time in the Atlanta area, as were 
pubic education campaigns, especially targeting gay men.  In fact, the CDC estimates that 
nearly 25% of the approximately 1.1 million people living with HIV/AIDS in the United 
States are undiagnosed (Centers for Disease Control 2008).  Again, structural barriers, 
mediated and reinforced by existing power relationships, offer a convincing explanation.  
Gary spoke of not only his personal struggle with finding a primary care physician, but 
also, as a pharmacy manager, his experiences with physicians who were homophobic and 
who often prescribed inappropriate combinations of ARV’s for their gay patients.  From 
Gary’s perspective these “mistakes” were probably not intentional, but, most likely, 
stemmed from underlying, or perhaps, unconscious systematic discrimination against gay 
men.  These vignettes offer case examples supporting the large literature showing that 
access to testing and treatment options does not equate to the utilization of those 
resources (Abadia-Berrero and Castro 2005; McCombie 1986; Smith 2003).  While this 
disjuncture is often conceptualized through a lens of stigma and discrimination, it is 
important to keep in mind the confluence of structural factors in addition to simple access 
which restrain the choices and priorities of the socially and economically marginalized.   
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One of the most serious emerging and least talked about structural issues is the 
phenomenon of rising prescription co-pays.  One of my informants, Gary, who is a 
pharmacy manager, spoke of the vast inequality which characterizes such co-pays.  
People living with HIV who access ART through Medicare or Medicaid often have 
prescription co-pays as low as 50 cents per prescription, while many people with private 
insurance can have co-pays up to $100 per prescription, depending on the type and 
quality of insurance coverage.  Gary spoke of an overriding ethic among the patients he 
serves of “trying not to go on Ryan White,” even if they face serious financial hardship 
due to paying $200-$300 a month, out of pocket, for their prescriptions.  Even though 
Ryan White based funding, such as ADAP and other local and state assistance programs, 
may be available to them, they often conceptualize their enrollment in the programs 
offered through Ryan White as taking a spot from someone who really needs it.  While 
this characterization may not be entirely accurate, from a funding standpoint, there is 
considerable apprehension among those with private insurance towards enlisting in Ryan 
White based programs.  Similarly Niehaus (1990) writes of the Gay Men’s Health Crisis, 
a community-based non-profit, “While the professionals with AIDS certainly aknowledge 
the value of such services for others, and on occasion would themselves serve as 
volunteers in these organizations, they often felt that they themselves has no need for the 
mutual assistance group services” (Niehaus 1990: 189).  In Atlanta, there is very little 
community-based and local education about who is, or should be, utilizing such programs 
and assistance.  This is a major area for social science research to target and help alleviate 
as the inequalities associated with differential prescription co-pays increases. 
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The structural limitations associated with access to ART - rising prescription co-
pays, access to and knowledge of education and testing services, different routes of 
access, be it private insurance or government funded programs, and systematic 
discrimination by the healthcare sector - are all byproducts of a larger ailment which is 
pervasive in healthcare in the United States.  Inequity of access is a complex and multi-
faceted issue which extends far beyond the reaches of the simple ability to pay for 
healthcare.  Although endemic poverty plays a large role in this inequity, the power 
structures which control, shape, and influence America’s healthcare system replicate that 
inequity on many levels.  In particular, gay men have long been segregated within the 
healthcare sector to primary care physicians who “specialize” in gay men’s health, from 
donating blood (Owings 2007), and have been labeled “at-risk” for contracting HIV.  In 
fact, the CDC continues to classify all sex between men as “high risk,” but “high risk” 
heterosexual sex only constitutes unprotected sex with a partner known to have been 
exposed to the HIV virus (Centers for Disease Control 2008b).  Of course, this definition 
seems quite outdated when heterosexual intercourse accounts for over 30% of new cases 
in 2006, nationally (Centers for Disease Control 2008b).  This type of marginalization 
continues to stem from early characterizations of HIV/AIDS as a “gay plague,” and my 
informants continue to internalize this hegemonic construction even after the statistical 
evidence and concerned public interest groups have debunked such notions.   
As the epidemic in the United States continues to grow and diversify, related 
support agencies are making systematic changes in policy and direction in order to keep 
up.  Over the last several years I have worked with a non-profit community-based 
HIV/AIDS-related testing and support agency which is doing just that.  The growth in 
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staff and resources devoted to outreach to African Americans, Latinos, non-native 
English speakers in general, and non-injecting drug users (especially methamphetamine 
users) has been considerable.  Because of the relatively progressive policy in the United 
States for supplying ART to people living with HIV/AIDS, the need for organizations 
such as this to provide them is greatly reduced.  Much of the work now is devoted to 
helping newly diagnosed people access available resources from both government and 
private sources.  The organization with which I work employs 40 full-time case managers 
for this purpose, and is the largest of its kind in the Atlanta area.   
Even as the epidemic continues to diversify, gay men, especially young gay men, 
continue to be a locus of infection and target for intervention strategies.  My informant, 
Gary, commented when talking about how his HIV status has affected his dating life that 
younger gay men are naïve about the consequences and severity of becoming infected.  In 
a more nihilistic view, my informant, Curtis, said, “anyone 25 and below has no excuse 
for getting infected, especially if they are middle class and gay.  The information is out 
there.”  What is interesting about Curtis’ comment is the explicit notion that class has 
something to do with prevention and education awareness.  While Curtis is essentially 
blaming the “victim” if they are middle class and gay, he does not see his own serostatus 
as preventable, because he is over 25 and told me he was diagnosed in 1982, before the 
mechanisms of HIV transmission were know.  However, there is an implicit 
understanding that structural limitations play a role in who is targeted for prevention 
efforts and who has the cultural capital to act on that knowledge. 
These findings and case studies, in particular, offer evidence of the extreme 
influence of structural impediments, personal agency, and a reflexive gaze on how my 
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study population thinks about and deals with living with HIV/AIDS.  The structural 
factors which not only limit access but shape how access is garnered in many ways form 
the foundation of how HIV/AIDS is conceptualized.  The fact that most of my 
participants consider access to ART to be a given allows them to reduce the impact of 
HIV on their lives, both mentally and physically, and “re-normalize.”  These factors both 
influence and are influenced by the level of personal agency that each person is able to 
wield within the healthcare sector and within their personal and sexual lives.  This agency 
is, to a large extent, determined by each person’s status in and knowledge of the existing 
power relationships which shape the American healthcare system.  All of these factors, 
then, contribute to how a person thinks, feels, and responds to their illness, namely a 
reflexive gaze.  That gaze is informed by an individual’s biomedical and social 
understandings of HIV/AIDS, mediated through healthcare providers, friends and family, 
the media, and, perhaps most importantly, hegemonic constructions of HIV/AIDS.  The 
hegemonic constructions which were of the most importance to my informants are those 
created and maintained through historic correlations between HIV/AIDS and gay 
identity.  It is, thus, a three-tiered paradigm, with definite transfers and influence between 
those tiers, which leads to the creation of HIV-related identities, within my study 
population.      
                                   
 
 
 
 
 
 
 77 
Chapter 7 
“This won’t be what kills me:” Conclusions and Directions for 
Future Research. 
 
 The findings of this study lend themselves to several conclusions and add to the 
greater body of literature in a number of ways.  The structural factors affecting access to 
ART are numerous and central to shaping how my informants think about and act 
towards HIV/AIDS.  This issue, coupled with varying levels of personal agency, has 
profound effects on each person’s ability to access not only ART, but the healthcare 
sector, generally, and information about prevention, available treatment options, and 
treatment funding sources, specifically.  I have found that these issues are paramount to 
the creation of a HIV-related identity among my informants.  In many cases such a 
process was mediated by the hegemonic influence of public health and media messages 
which linked gay identity with ubiquitous HIV infection.  It is, thus, the combination of a 
suite of factors – how access is garnered, levels of agency within the healthcare sector, 
structural factors, hegemonic constructions, behavioral practices, and the presence of 
preexisting identities – which contribute to the relationship that people with HIV/AIDS 
create with their illness.  
 These findings are significant to the scholarly literature in several ways.  They 
continue to demonstrate that structure and agency can not, and should not, be separated 
for analysis.  Many other contemporary social scientists have drawn attention to this issue 
when discussing HIV/AIDS research, most notably Paul Farmer, whose critique of 
medical anthropology suggests that anthropologists tend to over-emphasize or assume 
agency among the populations they study.  My findings would suggest that agency and 
structural factors are unable to be separated and each contributes to the effects and 
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outcomes of the other.  It is this confluence which then shapes that person’s relationship 
with their illness, in conjunction with society-level understandings or that illness, namely 
cultural models.  These cultural models are formed through the merging of how society 
thinks about and deals with an illness and the hegemonic discourse surrounding that 
illness.  In the case of HIV/AIDS, the development of technology and pharmaceuticals 
has fostered a re-conceptualization of it as a chronic, preventable, and treatable illness, 
and my informants echoed this notion.  If fact, my informant, Mark said, “I don’t think 
this is what will kill me.”  In addition, however, the early public health response to 
HIV/AIDS which characterized it as a “gay plague” continues to influence how my 
informants think about their condition; an inevitable consequence of social 
marginalization and a result of being the “other.”   
 We know that cultural models are fluid and dynamic and the introduction of ART 
has certainly resulted in the re-conceptualization of HIV/AIDS as a chronic illness.  
However, the continued association of gay men and HIV/AIDS has, disturbingly, not 
been altered despite drastic epidemiological shifts in incidence and prevalence.  The fact 
that many of my informants justified their serostatus by pointing to their sexual 
orientation is a disconcerting consequence of not only the hegemonic influence of early 
public health responses to HIV/AIDS, but also the social marginalization gay men 
continue to face, specifically within the healthcare sector.  It is obvious that this 
marginalization has been internalized by my informants and when seeking a way to deal 
with their diagnoses call upon it to explain “why them.”   
 These four factors, structural issues, personal agency, pre-existing identities, and 
the influence of cultural models and hegemony, have the greatest influence in shaping my 
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informants’ views and relationship with HIV/AIDS.  The reflexive gaze, the conduit of 
information and meaning between person and illness, is not a pure conduit, but 
manipulated by the cultural forces which shape how we think and act.  This does not 
mean, however, that the authoritative knowledge of the individual is diminished.  
Individual conceptions of what it means to have HIV/AIDS and “appropriate” responses 
to such a diagnosis vary and always have the possibility to resist culturally dominant 
views.  My informant, Jake, offers an interesting example of such a case.  While the rest 
of my informants placed their trust in biomedicine and their healthcare provider, Jake 
sought out alternative therapies and medical practitioners.  This is not meant to suggest 
that his relationship with his illness was any more valid or meaningful, but that the forms 
which such a reflexive gaze takes are varied and reflect individual agency, which do not 
always coincide with dominant or hegemonic constructions. 
 Throughout the course of this research my views about the nature of HIV-related 
identity have shifted considerably and the structural impediments which people face in 
obtaining education, testing, and treatment options have come, largely, to the forefront of 
that view.  However, these issues are only one factor in the greater scheme of what it 
means to be living with HIV/AIDS today.  It is clear that my informants developed 
relationships with their illness that are shaped and molded by these structural factors, but 
also shaped by cultural and historical notions of HIV/AIDS and personal feelings and 
beliefs.  It is also clear that each of these factors has influence over the others and the 
extent to which those issues manifest themselves is a byproduct of myriad aspects, 
including relative agency, the influence of dominant conceptions of HIV/AIDS on the 
individual, pre-existing identities, individual behaviors, and personal feelings and 
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experiences.  “Where economic access is less the question, the deeper dimensions of the 
health care system’s exploitation of illness are more apparent” (Niehaus 1990: 198).  The 
implications of such a complex web of connection and influence are, likewise, complex.  
It continues to be necessary to reduce the structural limitations faced by many people in 
accessing information, testing, and treatment options.  The rededication of resources 
within an American context is vital to achieve this end and a continued and increased 
outreach which focuses on behaviors, not sub-populations, deemed risky or high risk is 
essential.  Concurrently, debunking the myth that gay identity is a precursor and synonym 
for HIV infection is necessary.  It is a sad fact that most of my informants related these 
two concepts as a way of justifying their serostatus.  Such correlations may have the 
impact of reducing prevention strategies, such as practicing safer sex, among gay men 
who believe it is their destiny to become infected, whether such strategies are practiced or 
not.  Furthermore, such correlations maintain the current social marginalization that gay 
men continue to face as the “other,” or outside of “mainstream” society.  While the 
development of ART has brought about significant improvements in the way HIV/AIDS 
is dealt with and conceptualized in the United States, certain marginalized populations 
continue to bear the burden of epidemiological and social reality.  These trends inform 
how those people think about their illness and it is not until those hegemonic 
constructions, created and maintained by existing power relationships, are changed that 
the damage of early public health responses to HIV/AIDS can be undone.                   
HIV/AIDS offers a profound example for the disciplines of social science, 
especially anthropology.  Never before had the biological, clinical, pharmaceutical, and 
social effects of a worldwide pandemic evolved in tandem and been able to be 
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documented from a holistic perspective.  While disease is constantly “emerging,” and in 
many cases, re-emerging, the devastating effects of HIV, from a biological, etiological, 
social, political, and economic standpoint are unmatched in their severity, breadth, and 
complexity.  It is, perhaps, from the example of HIV, that we can better combat the next 
“deadly scourge.”  From an anthropological perspective, the knowledge we have gained 
about how people, as individuals and society at large, respond to the challenges faced by 
infection can inform how the public health and academic communities develop and 
implement prevention and treatment programs in the future.  
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Appendix A: 
 
Interview Schedule: 
 
1.  When were you first diagnosed with HIV?  How old were you?  Tell me about that 
experience? 
 
2.  How long have you been living with HIV?   
 
3.  Who have you disclosed your HIV status to? 
 
4.  How would you say your life changed, if at all, when you were first diagnosed?  
Medically?  Socially? 
 
5.  Are you currently antiretroviral therapy or another form of treatment?  If yes, how 
long have you been consistently using ARV treatment? 
 
6.  How is your ARV treatment financially provided for?  Insurance?  Government 
funding?  Out of pocket? 
 
7.  What type of ARV therapy are you using (specific drugs and combinations)?   
 
8.   Was there ever a period of time after you were diagnosed with HIV that you stopped 
taking your ARV medications? If so, please tell me about your decision to stop taking 
your medications. 
 
9. How has your life changed since you began treatment?  Physically?  Socially?  
Mentally? 
  
10.  Have you done any research about treatment options and how the HIV virus works 
beyond what your health care provider has given you? 
 
11.  How would you characterize your experiences with HIV in the past? 
 
12.  How would you characterize your experiences with HIV currently? 
 
13.  Do you feel more hopeful, less hopeful, or the same about ARV therapy now, then 
you did previously?  
 
14.  Tell me about the daily challenges regarding your ART regimen?  Do you find the 
process difficult? 
 
15.  Would you ever characterize your experiences living with HIV as stigmatizing?  Has 
that feeling changed over time?  If so, how?      
 
 
